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7General introduction
GENERaL INTRoducTIoN
Gliomas are the most common type of primary brain tumors in adults (incidence 5.97 
per 100.000 in the US (1)), and often have a dismal prognosis (2, 3). Based on their histo-
pathological features, gliomas can be subdivided into oligodendrocytic (OD), astrocytic 
(A) and mixed oligoastrocytic tumors (MOA). They are further subcategorized into vari-
ous malignancy grades according to the WHO2007 criteria. Oligodendrocytic and mixed 
oligoastrocytic tumors are separated into low-grade (II) and anaplastic tumors (III). 
Astrocytic tumors are further separated into pilocytic astrocytomas (PAs) (I), low-grade 
tumors (II), anaplastic tumors (III) and glioblastoma multiforme (GBM, grade IV) (4). 
GBMs are the most common and can either arise de novo (primary) or from previously 
diagnosed lower grade astrocytomas (secondary) (5). The patients’ prognosis is related 
to the type and grade of the tumor. For example, patients with a glioblastoma have a 
median survival of approximately one year, whereas patients with grade II OD have a 
more favorable prognosis with a median survival of 11.5 years (6). Apart from pilocytic 
astrocytoma, all glioma subtypes will eventually lead to death (6).
Current treatment options depend on the histological diagnosis in combination with 
clinical features (age, Karnofsky performance score (KPS)) and include surgical resec-
tion, radiotherapy and chemotherapy. The extent of resection is positively correlated 
with prolonged progression-free survival, improved seizure control and reduced risk 
of malignant transformation (7, 8). However, a complete resection of gliomas cannot 
be performed because individual glioma cells infiltrate the parenchyma of the brain 
(9). Especially in or nearby eloquent areas, resection is often stopped before complete 
resection is achieved to prevent postoperative neurologic deficits (10). The extent of 
tumor resection is therefore highly dependent on tumor location.
Treatment options for glioma patients
Radiotherapy is the recommended treatment for tumors that are at higher risk for ma-
lignant transformation, though this treatment is associated with significant side effects 
(11). The optimal dose and timing of RT has been investigated in many trials for LGG 
(12-14). No significant overall survival (OS) benefit was found in patients receiving low 
(45 Gy in 5 weeks or 50.4 Gy/28 fractions) versus high (59.4 Gy in 6.6 weeks or 64.8 Gy/36 
fractions) dose of RT (13, 14). Likewise, early versus late RT showed an improvement in 
progression-free survival (PFS), but not in OS (12).
A combination of Procarbazine, CCNU (lomustine) and vincristine (PCV) or temozolo-
mide (TMZ) are the choices for chemotherapy in patients with low grade or anaplastic 
gliomas. Part of PCV chemotherapy is administered intravenously and is associated 
with significant hematopoietic toxicity. TMZ on the other hand is easier to administer 
and better tolerated. In RTOG9802, a significant improvement in OS after adjuvant PCV 
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also shown to improve outcome (16-18). Similar improvements in PFS and OS after 
adjuvant PCV were obtained in anaplastic oligodendrogliomas and oligoastrocytomas 
(19-21). Whether PCV or TMZ gives similar survival benefit for patients is currently being 
investigated.
TMZ has also shown improved outcome in newly diagnosed glioblastomas (22, 23). 
Especially those patients containing a methylated MGMT promoter benefited from TMZ 
(23-25).
Novel treatment modalities
Unfortunately, despite these aggressive treatments, all gliomas eventually recur and 
therefore new treatment modalities are required. One of the recent drugs that have 
been tested is bevacizumab, a monoclonal antibody directed against the vascular en-
dothelial growth factor (VEGF). An improvement of PFS was observed in patients with 
newly diagnosed GBMs (26, 27). Unfortunately, no improvement of OS was noted in 
newly diagnosed GBMs (26, 27). The effect of bevacizumab on OS in recurrent GBMs is 
still under investigation (28).
Cilengitide is an αvβ3 and αvβ5 integrin inhibitor, which showed modest results in 
recurrent GBM patients (29, 30). In newly diagnosed GBM however, no additional benefit 
with cilengitide was observed (31, 32).
Another approach to treat gliomas involves using the immune system to clear the 
tumor. Examples of these include peptide-based vaccines like rindopepimut, a peptide-
based vaccine targeting EGFRvIII (33, 34). Dendritic cell vaccines are also currently being 
investigated (35). 
Molecular classification of gliomas
In gliomas, selection of treatment options is at least partly determined by histological 
classification of the tumor. However, a limitation of histological diagnosis and grading 
includes interobserver variability, which can lead to misdiagnosis of gliomas. For ex-
ample, patients diagnosed with a PA will need less aggressive treatment regimens than 
patients with grade II-IV gliomas. More accurate methods are required to overcome the 
limitation in the histopathological diagnosis of gliomas and provide a more effective 
and personalized treatment. Molecular subtyping of gliomas can be used to improve di-
agnosis, provide more accurate prognostic information and develop targeted therapies. 
Gliomas can be classified by their gene expression profile, DNA methylation profile or by 
their genetic changes.
Gene-expression based molecular classification of gliomas have shown a reasonable 
concordance between studies. Phillips et al. have identified three subtypes (proneural, 
mesenchymal and proliferative) in high-grade gliomas using supervised clustering (36). 
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Verhaak et al. identified four subtypes in GBMs: classical, neural, proneural and mesen-
chymal (37). Li et al. performed gene expression in all histological subtypes and identi-
fied two main groups as GBM-rich (mesenchymal) and OD-rich (proneural) separable 
into six subtypes by unsupervised clustering (38). Similarly, Gravendeel et al. identified 
six intrinsic glioma subtypes when clustering all histological subtypes of glioma (39). 
Several of these studies have shown that subtypes differ from histological classification 
of gliomas and that they are correlated to patient prognosis.
With the genome-wide methylation profiling of gliomas, two major glioma subtypes 
can be identified; CpG island methylator phenotype (CIMP)- and CIMP+ tumors (40-42). 
Patients with a CIMP+ phenotype have a longer survival than CIMP- tumors. Several 
groups have identified additional subtypes (40, 43).
Gliomas can also be classified on their genetic changes. For example, grade I pilocytic 
astrocytomas often have mutations or structural rearrangements in the BRAF gene (44, 
45). Grade II/III As and secondary GBMs frequently harbor mutations in the IDH1/IDH2, 
TP53 and ATRX genes (46-52). Primary GBMs are characterized by genetic aberrations in 
the three pathways (RTK, TP53 and RB) and frequently involve EGFR amplification, PTEN 
deletion, TERT gene promoter mutations; mutations in the IDH1 gene are infrequent 
in primary GBMs (53-59) Among oligodendrocytic tumors, the majority of grade II and 
anaplastic ODs exhibit combined loss of heterozygosity (LOH) of chromosome arms 1p 
and 19q and mutations in the genes IDH1/2, CIC, FUBP1 and TERT promoter (49, 59-62). 
In a recent paper of Aldape et al., integrated data from multiple platforms identified 
three subtypes of low-grade gliomas that were concordant with IDH, 1p19q, and TP53 
status. Low-grade gliomas with an IDH mutation and 1p19q co-deletion had the best 
clinical outcome. Patients with a low-grade glioma with mutations in IDH and without 
1p19q co-deletion consisted of mutations in TP53 and ATRX. Low-grade gliomas without 
mutations in IDH had a clinical outcome more similar to primary GBMs. Analyzing low-
grade gliomas based on IDH, TP53 and 1p19q status may allow classification of patients 
into distinct glioma subtypes with different clinical outcomes, making use of other 
platforms unnecessary (63).
Tumor biomarkers
Tumor biomarkers are molecular characteristics of the tumor that can aid diagnosis, 
provide prognostic information for the patient or predict response to a given treatment. 
(64). More recently, biomarkers are used to select subgroups of patients in targeted 
therapy or personalized medicine trials. (65). EGFRvIII expression for example is used as 
an inclusion criterium marker to investigate the effect of rindopepimut (a vaccine for 
EGFRvIII) in newly diagnosed and recurrent GBMs. The biomarkers that have shown clini-
cal relevance in gliomas will be described in more detail and include 1p19q deletions, 
mutations in IDH1/2, EGFR, BRAF and MGMT promoter methylation.
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Co-deletion of 1p19q
Co-deletion of chromosome arms 1p and 19q due to an unbalanced translocation of 
19p to 1q is a hallmark of pure ODs (66). Patients with 1p19q loss have a more favorable 
prognosis and are sensitive to alkylating agents such as PCV chemotherapy (19, 21). The 
high percentage of this genetic change suggested the presence of tumor suppressor 
genes on the remaining arms.
Recent exome sequencing studies indeed have identified mutations in two tumor 
suppressor genes, the CIC gene, on chromosome 19q and the FUBP1 gene on chromo-
some 1p (60-62). Their additional role on the outcome of patients with 1p19q loss is still 
under investigation.
IDH1/IDH2
Somatic mutations in the IDH1 gene were initially identified in 2008 by one of the first 
whole exome sequencing efforts (53). Similar genetic changes in the homologous IDH2 
enzyme were identified soon after (67). The IDH1 and IDH2 genes encode for proteins 
with identical metabolic activity but are localized in different subcellular compartments, 
cytoplasm/peroxisomes and mitochondria respectively. Wildtype IDH1 and IDH2 convert 
isocitrate into α-ketoglutarate and generate NADPH from NADP in this process. Both IDH1 
and 2 mutations are localized around the highly conserved codons 132 and 140/172, 
respectively, amino acids that are involved in substrate binding (68). IDH1 and IDH2 mu-
tations are often (but not always) mutually exclusive and always heterozygous. Mutant 
IDH1 or 2 have an altered substrate specificity; the protein binds to α-ketoglutarate and 
uses it as a substrate to produce the oncometabolite D-2-hydroxyglutarate (D-2-HG) 
(69). D-2-HG production from α-ketoglutarate by mutant IDH inhibits α-KG–dependent 
enzymes such as TET2. The TET family of dioxygenases (TET1, TET2, and TET3) catalyzes 
the hydroxylation of 5-methylcytosine in DNA; the first step in the demethylation of 
DNA. D-2-HG inhibits the formation of 5-hydroxymethylcytosine levels and so reduces 
DNA-demethylation. Indeed, in gliomas the CIMP-phenotype is highly associated with 
IDH1 mutations (70, 71). The competitive inhibition of a-ketoglutarate dependent on 
hydroxygenases ultimately results in a block in cellular differentiation, which is one of 
the hallmarks of cancer.
IDH1 and IDH2 mutations are frequently found in grade II/III gliomas, in secondary 
GBMs and in other neoplasms, AML (acute myeloid leukemia), chondrosarcomas and 
intrahepatic cholangiocarcinomas (72, 73). IDH1 mutations precede TP53 mutations 
and 1p19q co-deletion, which represent astrocytic and oligodendroglial differentiation 
markers respectively (46, 47, 62, 74). 
In gliomas, IDH-mutations serve as prognostic markers: IDH-mutated tumors have a 
more favorable prognosis than IDH-wildtype tumors (74-76). IDH-mutations may also be 
predictive for response to PCV in anaplastic oligodendrogliomas and for surgical resec-
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tion: only in mutant IDH1 gliomas an additional survival benefit associated with maximal 
surgical resection was found (77, 78).
EGFR
Strictly speaking, EGFR is neither a predictive nor prognostic biomarker that is used in 
the clinic. However, as EGFR is one of the most common genetic changes in primary 
GBMs (and as such aids the diagnosis of pGBMs), it is an active target for treatment and 
several clinical trials currently use the genetic changes in the EGFR locus as inclusion 
criterium.
EGFR gene amplification and activating mutations occur frequently in primary GBMs, 
and rarely in lower grade gliomas (54, 79). After amplification, additional genetic changes 
occur in the EGFR locus of which EGFRvIII is the most frequent activating mutant form 
in which the ligand-binding domain (exons 2-7) is deleted (53, 80). Missense mutations 
also have been identified in exons encoding the extracellular EGFR domains (81). All 
mutation types result in a constitutively activated RAS-RAF-MAPK, PI3K-AKT-mTOR and 
JAK-STAT pathway (82, 83).
In some studies, EGFR amplification or mutation was indicative for a worse long-term 
survival in GBM patients (84). Other studies however have failed to demonstrate an effect 
on survival (85). EGFR amplification or mutation may also predict response to tyrosine 
kinase inhibitors or serve as a target for immunotherapy (86, 87). EGFR targeted thera-
pies, such as monoclonal antibodies or tyrosine kinase inhibitors have been explored in 
patients with newly diagnosed or recurrent GBM, but did not reach significant results 
in phase II trials (88-90). EGFR is also frequently mutated in other cancer types includ-
ing pulmonary adenocarcinomas and breast cancer (91). The mutations found in these 
cancer types are different from GBMs, but both result in an activated EGFR pathway.
BRAF
BRAF belongs to the RAF serine threonine kinases family and is involved in directing 
cell growth via the MAPK and ERK pathways (92, 93). Duplications of this gene are fre-
quently found in pilocytic astrocytomas and rarely in other grades of astrocytic tumors 
(93, 94). The tandem duplication often (but not always) produces a fusion gene of the 
genes KIAA1549 and BRAF, such that the 5’ end of the KIAA1549 is fused to the 3’ end of 
BRAF (95). Most common fusion variants are KIAA1549:BRAF exon 16-exon 9 followed by 
KIAA1549:BRAF 15-9 (92, 96). The presence of the KIAA1549:BRAF gene fusion is signifi-
cantly associated with a better prognosis and can be used to distinguish prognostically 
favorable pilocytic astrocytomas from grade II astrocytomas (48).
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MGMT
The O-6-methylguanine DNA methyltransferase (MGMT) gene on chromosome 10q26 
encodes for a DNA repair enzyme that repairs damage induced by DNA alkylating 
agents (such as temozolomide) (97). The CpG island of the MGMT promoter is frequently 
methylated in gliomas. Methylation of the CpG island in the promoter region leads to 
altered chromatin structure and reduced binding of transcription factors resulting in 
silencing of the MGMT gene (98). Therefore, tumor cells with an unmethylated MGMT 
promoter are resistant to alkylating agents, while those having silenced MGMT are more 
chemosensitive (23-25). MGMT promoter hypermethylation therefore serves as a predic-
tive marker for response to temozolomide in newly diagnosed glioblastomas (23).
Additionally MGMT promoter hypermethylation has been associated with a more 
favorable prognosis in grade III gliomas (41, 76). There are several assays (MS-MLPA, 
MS-PCR) to measure MGMT promoter methylation. These assays interrogate different 
sets of CpG sites and have shown different outcome (23-25, 99-101). It is therefore 
important to select CpG sites that have sufficient predictive power when conducting 
an analysis. MGMT-STP27, identified using logistic regression, determines the MGMT 
promoter methylation status for use as a predictive response marker to TMZ (102). This 
model includes probes cg12434587 and cg12981133 and covers CpG sites within the 
DMR1 and DMR2 regions (99). DMR1 and DMR2 are two regions that lie within the MGMT 
promoter and play an important role in the transcriptional control of MGMT (102). CpG 
sites within DMR1 and DMR2 have shown good classification properties and prognostic 
value, making these regions a good target for methylation testing (99).
scope of this thesis
Although several prognostic and predictive biomarkers have been identified, there is 
still considerable need to improve on these. For example, there are patients with MGMT-
methylated promoters who perform poorly. Therefore, in chapters 1-3 of this thesis, we 
describe additional predictive biomarkers in two randomized clinical trials.
Although these predictive markers may help patients select treatment, the prognosis 
for glioma patients remains poor. Therefore, novel treatment modalities require to be 
developed. In this thesis, we have analyzed the functional effects of different mutations 
in EGFR (chapter 4) and of genes mutated at a low frequency in ODs (chapter 5). EGFR 
mutations are frequently detected in many types of cancer with different cancer types 
having distinct genetic mutations. If distinct EGFR mutations have different functional 
differences, they may lead to the development of mutation specific targeted therapies. 
Less attention has been paid to the role of genes mutated at low frequency in ODs with 
1p19q co-deletion. If these infrequent mutations play a role in tumorigenesis and pro-
gression, they may offer new therapeutic options for the treatment of ODs.
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In summary, this thesis describes several methods to identify predictive markers in 
gliomas and the functional consequences of different mutations in EGFR and infrequent 
gene mutations in ODs. 
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Purpose
Intrinsic glioma subtypes (IGSs) are molecularly similar tumors that can be identified 
based on unsupervised gene expression analysis. Here, we have evaluated the clinical 
relevance of these subtypes within European Organisation for Research and Treatment 
of Cancer (EORTC) 26951, a randomized phase III clinical trial investigating adjuvant 
procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligoden-
droglial tumors. Our study includes gene expression profiles of formalin-fixed, paraffin-
embedded (FFPE) clinical trial samples.
Patients and Methods
Gene expression profiling was performed in 140 samples, 47 fresh frozen samples and 
93 FFPE samples, on HU133_Plus_2.0 and HuEx_1.0_st arrays, respectively.
Results
All previously identified six IGSs are present in EORTC 26951. This confirms that differ-
ent molecular subtypes are present within a well-defined histologic subtype. Intrinsic 
subtypes are highly prognostic for overall survival (OS) and progression-free survival 
(PFS). They are prognostic for PFS independent of clinical (age, performance status, and 
tumor location), molecular (1p/19q loss of heterozygosity [LOH], IDH1 mutation, and 
MGMT methylation), and histologic parameters. Combining known molecular (1p/19q 
LOH, IDH1) prognostic parameters with intrinsic subtypes improves outcome prediction 
(proportion of explained variation, 30% v 23% for each individual group of factors). 
Specific genetic changes (IDH1, 1p/19q LOH, and EGFR amplification) segregate into dif-
ferent subtypes. We identified one subtype, IGS-9 (characterized by a high percentage 
of 1p/19q LOH and IDH1 mutations), that especially benefits from PCV chemotherapy. 
Median OS in this subtype was 5.5 years after radiotherapy (RT) alone versus 12.8 years 
after RT/PCV (P = .0349; hazard ratio, 2.18;95% CI, 1.06 to 4.50).
conclusion
Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome predic-
tion when combined with other prognostic factors. Tumors assigned to IGS-9 benefit 
from adjuvant PCV.
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INTRoducTIoN
Unsupervised analysis of gene expression profiling identifies subgroups of tumors that 
are molecularly similar. This approach has been used to identify distinct intrinsic sub-
types of cancer and provides an objective method to classify tumors (1–4). In gliomas, 
the identified intrinsic subtypes reportedly correlate better with patient prognosis than 
histology (5–9). Intrinsic glioma subtypes (IGSs) are not only similar on the RNA level, but 
specific genetic changes also segregate in distinct intrinsic subtypes (8,10). Therefore, it 
is likely that each molecular subtype will require its own treatment paradigm.
True validation of the prognostic relevance of the IGSs requires analysis on homo-
geneously and prospectively treated patients, ideally within a randomized clinical trial. 
One of the main problems in analyzing clinical trial samples is that they are often of poor 
quality; most are formalin-fixed, paraffin-embedded (FFPE) samples (11).
However, recent technologic advances have enabled high-throughput analysis of FFPE 
material, including expression arrays (12–14). In a large cohort of paired fresh frozen 
(FF)-FFPE samples, we recently demonstrated that differences in mRNA expression are 
retained in FFPE samples. Importantly, the assignment to one of six IGSs was identical 
between the FF-FFPE matched samples in 87% of cases (15), and the intrinsic subtypes 
remain highly prognostic for survival. These results demonstrate that FFPE material can 
be used for expression profiling. 
Not all patients with glioma respond similarly to treatment. For example, glioblasto-
mas with a methylated O6-methylguanine-methyltransferase (MGMT) promoter respond 
better to treatment with temozolomide (16,17). In oligodendrogliomas, uncontrolled 
trials indicated that loss of heterozygosity (LOH) on 1p/19q is predictive for response 
to procarbazine, lomustine, and vincristine (PCV) chemotherapy (18,19). Selection of 
patients who benefit most from particular therapeutic regimens helps to improve treat-
ment efficacy and to potentially avoid toxicity in patients who are unlikely to benefit 
from that therapy anyway.
European Organisation for Research and Treatment of Cancer (EORTC) 26951 is a ran-
domized phase III clinical trial investigating whether the addition of PCV chemotherapy 
to radiotherapy (RT) would improve overall survival (OS) and progression-free survival 
(PFS) in patients with anaplastic oligodendroglioma (AOD) or anaplastic mixed oligoas-
trocytoma (AOA). This trial showed that the addition of six cycles of PCV after 59.4 Gy of 
RT increases OS and PFS in these tumors (20). However, some patients seemed to benefit 
more from the addition of PCV treatment than others (21).
Here, we have evaluated the clinical relevance of intrinsic subtypes within EORTC 
26951. Our study is the first to use gene expression profiling on FFPE clinical trial samples. 
Our data validate that intrinsic subtypes of glioma are prognostic for survival. Intrinsic 
subtypes improve outcome prediction when combined with other known prognostic 
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parameters (1p/19q LOH and IDH1 mutation), although this increase is not significant. 
Our data also indicate that patients with tumors assigned to a specific intrinsic subtype 
benefit from PCV treatment.
PaTIENTs aNd METhods
Patient samples
Patients were considered eligible for EORTC 26951 if they had been diagnosed by the 
local pathologist with an AOD or an AOA according to the 1993 WHO classification. 
Details of the eligibility criteria and the CONSORT flow diagram have been described 
previously (21) and are shown in Figure 1. A central pathology review was conducted on 
345 of 368 samples and on 136 of 140 samples used in the present study. Four samples 
were omitted in the multivariate analysis that included review diagnosis as a factor. 
figure 1. 
Randomly assigned
n=368
Allocated to RT/PCV (n=185)
Never started RT (n=5)
 Early PD (n=1)
 Patient refusal (n=2)
 Other (n=2)
Never started PCV (n=19)
 Early PD (n=8)
 Patient refusal (n=5)
 Other (n=3)
 Unknown (n=3)
Allocated to RT (n=183)
 Randomly assigned
 in wrong trial (n=1)
Progression (n=107)
Further treatment:
 PCV (n=14)
 Other chemotherapy (n=74)
 Surgery (n=32)
 Other (n=21)
Progression (n=131)
Further treatment:
 PCV (n=90)
 Other chemotherapy (n=65)
 Surgery (n=30)
 Other (n=30)
CONSORT diagram. PCV, procarbazine, lomustine, and vincristine; PD, progressive disease; RT, radiotherapy.
Intrinsic glioma subtypes are prognostic and predict benefit from PCV 27
All analysis using histologic diagnosis made use of the review diagnosis. Patient and 
sample characteristics are detailed in the Data Supplement. Analysis of 1p/19q LOH, 
EGFR amplification, IDH1 mutations, and MGMT promoter methylation on EORTC 26951 
samples has been described previously (21–23).
RNa Isolation and array hybridization
Total RNA extraction, purification, and quantification from FF and FFPE material were 
reported previously (8,15). RNA (150 ng) from FF and FFPE tissues was used for expres-
sion profiling. FF samples (n = 47) were profiled as described on HU133plus 2.0 arrays 
(Affymetrix, High Wycombe, United Kingdom) (8); FFPE samples (n = 93) were profiled 
using HuEx_1.0_st arrays (Affymetrix) in combination with Nugen Ovation kits (Nugen, 
San Carlos, CA), as reported (13,15).
statistical analysis
Samples were assigned to one of the six intrinsic molecular subtypes of glioma using 
ClusterRepro (an R package; http://crantastic.org/packages/clusterRepro) as described 
previously, omitting control cluster 0 (8,24). Previously, these intrinsic subtypes were 
designated cluster followed by the cluster number (0, 9, 16, 17, 18, 22, or 23). Here, we 
annotate these clusters as IGSs followed by the same cluster number (eg, IGS-9). Other 
groups have also described molecular classification methods (7,9),(10); the overlap with 
The Cancer Genome Atlas classification is detailed in the Data Supplement (for other 
comparisons, see Gravendeel et al (8)). Samples assigned to IGS-9 and IGS-17 generally 
are assigned to the proneural subtype, IGS-18 to the classical subtype, and IGS-23 to the 
mesenchymal subtype. Neural subtypes are assigned to either IGS-17 or IGS-23.
Differences between the Kaplan-Meier survival curves were calculated using the 
log- rank (Mantel-Cox) test using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA). Comparisons between frequencies were calculated using 
the Fisher’s exact test. In this exploratory analysis, P < .05 was considered to indicate 
significant differences. The importance of groups of prognostic factors was compared 
using the percentage of explained variation (PEV) developed by Heinze and Schemper 
(25) for Cox regression using SAS macros (SAS Institute, Cary, NC). A PEV of at least 20% is 
considered a minimum requirement for a model to provide sufficiently precise individual 
PFS or OS predictions (26,27). PFS and OS were computed from random assignment to 
date of event (progression and/or death) or censored at the date of last visit.
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REsuLTs
Patients and samples
Out of 368 patients within the EORTC 26951 trial, a total of 140 samples of were available 
for the current study; for the other patients, the amount of material was insufficient. Of 
the samples, 47 were FF and 93 were FFPE. Seventy-three patients had been assigned 
to the RT plus PCV chemotherapy arm, and 67 patients had been assigned to the RT 
only arm. Our cohort of samples from the EORTC 26951 study did not differ from the 
entire EORTC 26951 cohort (368 patients) with respect to age, sex, performance status, 
diagnosis, tumor location, IDH1 mutation, 1p/19q LOH, EGFR amplification, MGMT pro-
moter methylation, OS, and PFS (Table 1). However, OS within the RT only treatment 
arm of included patients was worse compared with OS in patients not included (OS: 
1.6 v 3.7 years, respectively; P = .009; hazard ratio [HR], 1.59; 95% CI, 1.12 to 2.25; PFS: 
0.8 v 1.4 years, respectively; P = .012; HR, 1.55; 95% CI, 1.10 to 2.17), even when cor-
rected for known clinical (age, extent of resection, sex, and performance status) and 
molecular (1p/19q LOH) characteristics and histologic review diagnosis. There were no 
such differences in the RT-PCV arm. This effect is likely a result of difference in patient 
selection in the hospitals but not related to tissue sampling. Of note, at the time of 
random assignment, patients were stratified per center. Of the included samples, there 
were no differences in clinical, molecular, or histologic characteristics between the two 
treatment arms (Data Supplement). A detailed analysis of patients included versus not 
included is shown in the Data Supplement.
Intrinsic subtypes are Prognostic for os and Pfs
Expression profiling was performed on a total of 140 samples of patients treated within 
EORTC 26951. All expression profiles were then assigned to one of six predefined in-
trinsic subtypes. These molecularly similar intrinsic subtypes were identified previously 
and are based on unsupervised gene expression analysis (8). All six IGSs were identified, 
which shows that patients with different molecular subtypes were enrolled within this 
trial under the same histopathologic diagnosis. After assignment, IGS-9, IGS-16, IGS-17, 
IGS-18, IGS-22, and IGS-23 contained 50, two, 26, 27, eight, and 27 patients, respectively. 
The histologic composition (both original and review diagnosis) of subtypes is depicted 
in the Data Supplement. The intrinsic subtypes were highly prognostic for both OS 
and PFS. The median OS times for IGS-9, IGS-17, IGS-18, and IGS-23 were 8.5, 2.8, 1.2, 
and 1.0 years, respectively; and the median PFS times were 5.7, 1.8, 0.5, and 0.5 years, 
respectively (Fig 2). IGS-16 and IGS-22 contained too few samples to draw conclusions. 
Details for IGS-22 are listed in the Data Supplement. The subtype-specific differences in 
survival were highly similar to previously reported differences using FF archival samples 
and confirm the prognostic power of intrinsic subtyping (8). Even within the 1p/19q 
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Table 1. Comparison of baseline characteristics. 
baseline characteristics
P-value
Included in the cluster analysis
TotalNo Yes
N=228 (%) N=140 (%) N=368 (%)
age Median Range 49.5 19.4 - 68.7 49.4 18.6 - 68.7 49.5 18.6 - 68.7 0.57
obs (o) 228 140 368
sex Male 123 (53.9) 89 (63.6) 212 (57.6) 0.08
female 105 (46.1) 51 (36.4) 156 (42.4)
Performance 
status
0. 81 (35.5) 53 (37.9) 134 (36.4) 0.75
1.0 107 (46.9) 64 (45.7) 171 (46.5)
2.0 36 (15.8) 22 (15.7) 58 (15.8)
histological 
diagnoses
aod 173 (75.9) 93 (66.4) 266 (72.3) 0.04
aoa>25% o 53 (23.2) 47 (33.6) 100 (27.2) 
central diagnosis aod 100 (43.9) 76 (54.3) 176 (47.8) 0.02
aoa 46 (20.2) 36 (25.7) 82 (22.3) 
LGG 28 (12.3) 11 (7.9) 39 (10.6) 
hGG 26 (11.4) 13 (9.3) 39 (10.6) 
other 
Missing 
10 (4.4)
18 (7.9)
0 (0.0) 
4 (2.9)
10 (2.7) 
22 (6.0) 
Tumor location Elsewhere 119 (52.2) 71 (50.7) 190 (51.6) 0.83
frontal 109 (47.8) 69 (49.3) 178 (48.4) 
Idh1 mutation Normal 41 (18.0) 58 (41.4) 99 (26.9) 0.37
Mutated 39 (17.1) 44 (31.4) 83 (22.6) 
1p19q Loh Non codeleted 141 (61.8) 95 (67.9) 236 (64.1) 0.51
codeleted 44 (19.3) 36 (25.7) 80 (21.7) 
EGfR mutation Normal 111 (48.7) 82 (58.6) 193 (52.4) 0.76
amplified 32 (14.0) 26 (18.6) 58 (15.8) 
MGMT promoter 
methylation
unmethylated 14 (6.1) 17 (12.1) 31 (8.4) 0.61
Methylated 57 (25.0) 64 (45.7) 121 (32.9) 
Pfs obs (o);hR (95% cI) 181; 1.00 117; 1.16 (0.92, 1.46) 0.21
Median (95% cI) (months) 19.65 (15.38, 33.35) 14.52 (9.63, 21.13)
% at 2 Year(s) (95% cI) 48.02 (41.39, 54.34) 39.29 (31.20, 47.26)
os obs (o); hR (95% cI) 168; 1.00 113; 1.25 (0.99, 1.59) 0.06
Median (95% cI) (months) 43.89 (30.03, 61.17) 26.87 (18.69, 38.31)
% at 2 Year(s) (95% cI) 63.44 (56.81, 69.33) 51.43 (42.87, 59.33)
Abbreviations: Obs: observation events; AOD: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocy-
toma; LGG: low grade glioma; HGG: glioblastomas and anaplastic astrocytoma; HR: hazard ratio; CI: confi-
dence interval; PFS: progression-free survival; OS: overall survival. P<0.01 is considered statistically signifi-
cant. The missing values are not included in the table and are the remaining percentages.
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codeleted patient cohort, IGS subtyping remained prognostic. Conversely, 1p/19q sta-
tus was also prognostic within patients assigned to IGS-9 (Data Supplement).
In multivariate analysis, intrinsic subtype was a significant prognostic factor that was 
independent from clinical (age, sex, performance status, and type of surgery), molecular 
(1p/19q LOH), and histologic (local diagnosis or review diagnosis) parameters (Table 
2). Tissue type (FF or FFPE) was not a prognostic variable in univariate or multivariate 
analysis. When IDH1 mutation status was included in this analysis, intrinsic subtyping 
remained an independent prognostic factor for PFS (P = .003) but not OS (P = .052).
figure 2. 
Kaplan-Meier survival curves of (A) overall survival (OS) and (B) progression-free survival (PFS) of the four 
major intrinsic glioma subtypes (IGSs) to which the patients from the European Organisation for Research 
and Treatment of Cancer (EORTC) 26951 trial were assigned. Survival is depicted as time (years) since ran-
dom assignment. The four IGSs were highly prognostic for both OS and PFS because patient prognosis was 
different for each IGS. Only two and eight samples were assigned to IGS-16 and IGS-22, respectively (not 
shown).
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When MGMT promoter methylation was included, intrinsic subtyping remained 
an independent prognostic factor for both PFS (P < .001) and OS (P = .008), although 
the number of patients analyzed became relatively small (n = 80). Of note, even in the 
confirmed AOD tumors at central pathology review, each histologic subtype was found 
to contain several intrinsic subtypes. Within the group of central pathology review–con-
firmed AOD and AOA tumors or within the group of tumors with 1p/19q LOH, intrinsic 
subtype remains an independent prognostic factor.
Distribution of 1p/19q LOH (P < .001), MGMT (P = .007), IDH1 (P < .001), and EGFR (P 
<.001) was significantly different between clusters. 1p/19q LOH was significantly more 
frequently present in tumors assigned to IGS-9 (29 of 46 samples, 63%) compared with 
IGS-17 (six of 25 samples, 24%), IGS-18 (zero of 26 samples, 0%), and IGS-23 (zero of 25 
samples, 0%; Fig 3). EGFR amplification was predominantly observed in IGS-18 (14 of 24 
samples, 58%) and, to a lesser extent, in IGS-23 (eight of 21 samples, 38%). EGFR ampli-
fication was rarely observed in samples assigned to IGS-9 (three of 39 samples, 7.6%) 
and IGS-17 (zero of 19 samples, 0%). IGS-9 and IGS-17 were more often associated with 
MGMT methylation and/or IDH1 mutation compared with IGS-18 and IGS-23 (Fig 3 and 
Data Supplement). As previously reported, CpG island methylation phenotype–positive 
tumors segregated in IGS-9 and IGS-17, whereas CpG island methylation phenotype– 
negative tumors segregated in IGS-18 and IGS-23 (17).
Molecular parameters (28) (IDH1 and 1p/19q LOH) and intrinsic subtypes are both 
important prognostic factors. To assess the added predictive value for PFS of intrinsic 
subtyping, we combined molecular (IDH1 and 1p/19q LOH) data with intrinsic subtypes 
Table 2. Analysis of OS by intrinsic subtyping 
Number of observations
Number of failures
126
102
P-value HR 95% CI for HR
Intrinsic subtype 0.001 1.06 1.03 - 1.12
Age 0.002 1.03 1.01 - 1.05
Sex 0.530 0.87 0.57 - 1.34
Type of surgery 0.016 0.67 0.49 - 0.93
Performance status 0.011 1.46 1.09 - 1.94
1p19qLOH 0.000 0.32 0.17 - 0.59
Review diagnosis 0.086 0.82 0.66 - 1.03
Abbreviations: HR: hazard ratio (compared to RT only arm); CI: confidence interval. Calculations are based 
on 126 observations. Type of surgery categories included: biopsy, partial resection and total resection. Per-
formance status is based on WHO-ECOG scoring (0, 1 or 2) as described in(20). All categories were used as 
variable in the analysis.
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and assessed the PEV by the two models. Both molecular parameters and intrinsic sub-
types had comparable PEV (Data Supplement). This does not mean that both models 
explain the same variability. However, the combined model has a larger PEV of 30% 
compared with 23% for each individual group of factors, although this difference is not 
statistically significant.
Prediction of benefit from adjuvant PcV
We then evaluated whether the benefit from adjuvant PCV chemotherapy was specific 
to selected intrinsic subtypes. The addition of adjuvant PCV improved OS in samples 
assigned to IGS-9 (12.8 years in the RT-PCV arm v 5.5 years in the RT only arm; P = .035; 
HR, 2.18; 95% CI, 1.06 to 4.50); an improvement was also observed for PFS (12.8 years in 
the RT-PCV arm v 3.6 years in the RT only arm; P = .0018; HR, 3.18; 95% CI, 1.54 to 6.59). 
Data are shown in Figure 4 and Table 3. PCV treatment also improved PFS, but not OS, in 
figure 3. 
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Genetic differences between intrinsic glioma subtypes (IGSs). Specific genetic changes segregate into dis-
tinct IGSs. 1p/19q loss of heterozygosity (LOH) was predominantly observed in tumors assigned to IGS-
9 and, to a lesser extent, tumors assigned to IGS-17 but was not seen in tumors assigned to IGS-18 and 
IGS-23. IDH1 mutations (mut) were significantly more observed in samples assigned to IGS-9 and IGS-17 
compared with IGS-18 and IGS-23. EGFR amplification (amp) was predominantly identified in IGS-18 and 
IGS-23 but rarely identified in samples assigned to IGS-9 and IGS-17. This segregation was highly similar to 
that reported by us previously using archival samples and demonstrates that each IGS has a different set of 
causal genetic changes (8).
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samples assigned to IGS-18 (0.8 years in the RT-PCV arm v 0.4 years in the RT only arm; P 
= .028; HR, 2.51; 95% CI, 1.10 to 5.69). A trend toward an increase in both OS and PFS was 
observed between the two treatment arms in samples assigned to IGS-17 (OS: 5.4 v 1.8 
years in RT-PCV and RT only arms, respectively; P = .096; HR, 2.21; 95% CI, 0.87 to 5.60; 
PFS: 2.2 v 1.0 years in RT-PCV and RT only arms, respectively; P = .109; HR, 2.12; 95% CI, 
0.85 to 5.30). No difference in PFS or OS was observed between the treatment arms in 
samples assigned to IGS-23. Interaction tests for the effects of treatment across intrinsic 
subtypes were not significant for both PFS and OS (Data Supplement).
dIscussIoN
In this study, we performed intrinsic subtyping within a prospective clinical trial, EORTC 
26951. Our data demonstrate that all six IGSs are present in EORTC 26951, despite the 
fact that only AODs and AOAs (as diagnosed by the local pathologist) were included 
in this study. After central pathology review, each histologic diagnosis still contained 
various intrinsic subtypes. Similar to reports in archival samples, the intrinsic subtypes 
are an independent prognostic factor both for OS and PFS. Combining known mo-
lecular (1p/19q LOH and IDH1) prognostic parameters with intrinsic subtypes improves 
outcome prediction, although this difference is not significant (PEV of 30% v 23% for 
individual groups of factors).
Histologic classification of gliomas is troublesome and subject to interobserver 
variation (29). In this study, we confirm that expression profiling, compared with the 
diagnoses made by the local pathologists, is a more accurate and objective method 
to classify gliomas (6–10,30–34). Also similar to reports on archival samples, specific 
genetic changes (IDH1, 1p/19q LOH, and EGFR amplification) segregate into different 
subtypes. Therefore, intrinsic subtypes are not only similar in their RNA expression pro-
file, but are also similar on the DNA level in their genetic aberrations. Our data validate 
Table 3. Median Overall and Progression-free survival per treatment arm. 
overall survival Progression-free survival
Median survival 
(years) Hazard Ratio,
[95%CI]
P-value
Median survival 
(years) Hazard Ratio,
[95% CI]
P-value
RT RT/PCV RT RT/PCV
IGs-9 5.5 12.8 2.18; [1.06, 4.50] 0.0349 3.6 12.8 3.18; [1.54, 6.59] 0.0018
IGs-17 1.8 5.4 2.21; [0.87, 5.60] 0.0962 1.0 2.2 2.12; [0.85, 5.30] 0.1086
IGs-18 1.1 1.4 1.43; [0.66, 3.12] 0.3669 0.4 0.8 2.51; [1.10, 5.69] 0.0280
IGs-23 1.1 1.0 0.89; [0.39, 2.02] 0.7771 0.6 0.5 0.98; [0.44, 2.18] 0.9678
Abbreviations: IGS: intrinsic glioma subtype; RT: radiotherapy; RT/PCV: radiotherapy followed by procarba-
zine, lomustine and vincristine chemotherapy. 
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figure 4. 
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Kaplan-Meier survival curves of the four intrinsic glioma subtypes (IGSs) per treatment arm. (A and B) Ad-
juvant procarbazine, lomustine, and vincristine (PCV) chemotherapy improved overall survival (OS) and 
progression-free survival (PFS) in samples assigned to IGS-9. (C and D) A trend toward an increase in both 
OS and PFS is seen between the two treatment arms in samples assigned to IGS-17. (E and F) Adjuvant PCV 
also improved PFS, but not OS, in samples assigned to IGS-18. (G and H) No difference between the two 
treatment arms was observed for both OS and PFS in samples assigned to IGS-23. Patients with one specific 
IGS (IGS-9) seem to benefit from adjuvant PCV chemotherapy, whereas patients with tumors assigned to 
IGS-23 do not. In this figure, survival is depicted as time (years) since random assignment. RT, radiotherapy.
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the prognostic significance of intrinsic subtypes, and therefore intrinsic subtyping can 
be used to determine the molecular heterogeneity of samples included in clinical trials.
As said, clinical trial samples are often of poor quality because most are FFPE samples 
(11). However, recent technologic advances have indicated that expression profiling is 
feasible on FFPE material (12,13,15).
One of the limitations of the current study is that we were unable to determine the 
intrinsic subtype of all samples from EORTC 26951. Although most characteristics of 
samples included versus those not included are similar, this argues for a validation of 
our results in an independent cohort. 
1p/19q and IDH are powerful low-cost tools for molecular classification. However, 
these single molecular markers provide limited information and may miss, for example, 
tumors with only partial 1p/19q deletions (35). In addition, approximately 30% of tumors 
with 1p/19q LOH do not have an IDH1 mutation. Because of these limitations, we believe 
that single molecular marker analysis will be replaced by high-throughput assays. Here, 
we demonstrate that IGS classification improves outcome prediction and thus provides 
additional value for patients. Long-term follow-up of this trial shows that adjuvant PCV 
improves OS in AOA and AOD. Here, we further demonstrate that not all patients benefit 
equally from this treatment. Samples assigned to IGS-9 (characterized by a high percent-
age of 1p/19q LOH and IDH1 mutations) significantly benefit from PCV chemotherapy, 
whereas samples assigned to IGS-23 do not show any improvement in outcome (neither 
PFS nor OS). This outcome for IGS-9 samples is remarkable because there was a large 
degree of crossover in the RT only arm at time of progression (21). 
Tumors with 1p/19q LOH have been reported to show durable responses to chemo-
therapy (18,19,36). Independently, both the EORTC 26951 trial and its North American 
counterpart Radiation Therapy Oncology Group (RTOG) 9402 have shown that the 
addition of PCV to RT improved OS in 1p/19q codeleted oligodendrogliomas (37,38). 
Our data validate these observations because IGS-9 contains gliomas with the highest 
percentage 1p/19q LOH. Moreover, the median survival time between the RT-PCV and 
RT only arm is highly comparable to the median survival observed in RTOG 9402 (14.7 
years in the RT-PCV arm v 7.3 years in the RT only arm in the RTOG 9402 trial and 12.8 
years in the RT-PCV arm v 5.5 years in the RT only arm for IGS-9 samples in the EORTC 
26951 trial). It should be noted that not all tumors assigned to IGS-9 had 1p/19q LOH (19 
of 46 tumors), and conversely, not all tumors with 1p/19q LOH were assigned to IGS-9 
(29 of 36 tumors). Similarly, 18 of 55 tumors assigned to IGS-9 or IGS-17 did not have 
an IDH1 mutation, and seven of 44 tumors with an IDH1 mutation were not assigned 
to IGS-9 or IGS-17. Although we show that combining known molecular (1p/19q LOH 
and IDH1) prognostic parameters with intrinsic subtypes improves outcome prediction, 
which of these techniques can best predict response to PCV chemotherapy remains to 
be determined; numbers in the current study are too low for a formal comparison.
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Identifying patients who do not benefit from PCV chemotherapy is of equal clinical 
relevance. In our study, samples assigned to IGS-18 or IGS-23 showed no benefit from 
PCV chemotherapy in OS (although an increase in PFS was observed for IGS-18). In RTOG 
9402, OS was not improved by PCV chemotherapy in AODs and AOAs that retained 
either 1p and/or 19q. Combined, these data indicate that patients harboring an AOD 
or AOA that have retained 1p and/or 19q, assigned to IGS-18 or IGS-23, do not show a 
benefit in OS from PCV chemotherapy.
Samples assigned to IGS-17 showed a trend toward improved outcome from PCV 
chemotherapy, both in PFS and OS. IGS-17 contains predominantly tumors that have re-
tained 1p/19q but have IDH1 mutations. A similar trend toward improved outcome was 
observed in the entire EORTC 26951 cohort tumors with retained 1p/19q and mutated 
IDH1. Nevertheless, our sample cohort is relatively modest in size (N = 140), and our 
analysis is post hoc (retrospective testing), which is hypothesis generating. Therefore, 
our data should be validated in an additional independent cohort to firmly establish the 
predictive effect of these intrinsic molecular subtypes.
Interestingly, in a separate clinical trial (EORTC 22981/26981) on glioblastoma, 
patients with tumors assigned to IGS-18 also did not show a marked response to the 
addition of temozolomide to RT (8,39). In this study, too few samples were assigned to 
other subtypes to draw firm conclusions. It should be noted that there are some impor-
tant differences between EORTC 26951 and EORTC 22981/26981. For example, EORTC 
22981/26981 examined the efficacy of temozolomide chemotherapy in combination 
with RT as opposed to PCV. However, PCV and temozolomide are both alkylating agents 
with similar mechanism of action. Another important difference is the histologic subtype 
investigated; only glioblastomas were included in EORTC 22981/26981, whereas EORTC 
26951 included AODs and AOAs. However, intrinsic subtypes have similar molecular 
and clinical characteristics and are independent of histologic diagnosis. Therefore, we 
hypothesize that samples assigned to a defined intrinsic subtype will show similar re-
sponses to similar chemotherapy regimens regardless of histologic diagnosis.
In summary, we demonstrate, on clinical trial samples and using FFPE material, that 
intrinsic molecular subtypes are highly prognostic for OS and PFS. Our data indicate 
that at least one intrinsic subtype of glioma responds favorably to PCV chemotherapy. 
Intrinsic subtypes are easily determined, and therefore, this approach provides a novel, 
straightforward, and promising way to improve outcome prediction when combined 
with other prognostic factors.
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Purpose
The long-term follow-up results from the EORTC 26951 trial showed that the addition 
of procarbazine, CCNU, and vincristine (PCV) after radiotherapy increases survival in 
anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA). However, some patients 
appeared to benefit more from PCV treatment than others. 
Experimental design
We conducted genome-wide methylation profiling of 115 samples included in the 
EORTC 26951 trial and extracted the CpG island hypermethylated phenotype (CIMP) and 
MGMT promoter methylation (MGMT-STP27) status.
Results
We first show that methylation profiling can be conducted on archival tissues with a 
performance that is similar to snap-frozen tissue samples. We then conducted methyla-
tion profiling on EORTC 26951 clinical trial samples. Univariate analysis indicated that 
CIMP+ or MGMT-STP27 methylated tumors had an improved survival compared with 
CIMP− and/or MGMT-STP27 unmethylated tumors [median overall survival (OS), 1.05 
vs. 6.46 years and 1.06 vs. 3.8 years, both P < 0.0001 for CIMP and MGMT-STP27 status, 
respectively]. Multivariable analysis indicates that CIMP and MGMT-STP27 are significant 
prognostic factors for survival in presence of age, sex, performance score, and review 
diagnosis in the model. CIMP+ and MGMT-STP27 methylated tumors showed a clear 
benefit from adjuvant PCV chemotherapy: the median OS of CIMP+ samples in the RT 
and RT-PCV arms was 3.27 and 9.51 years, respectively (P = 0.0033); for MGMT-STP27 
methylated samples, it was 1.98 and 8.65 years. There was no such benefit for CIMP- or 
for MGMT-STP27 unmethylated tumors. MGMT-STP27 status remained significant in an 
interaction test (P = 0.003). Statistical analysis of microarray (SAM) identified 259 novel 
CpGs associated with treatment response.
conclusions
MGMT-STP27 may be used to guide treatment decisions in this tumor type.
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INTRoducTIoN
In 1995, a large European phase III clinical trial (“EORTC 26951”) was initiated to examine 
the effects of adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in 
anaplastic oligodendroglial tumors [oligodendrogliomas (AOD) and oligoastrocytomas 
(AOA); (1). The long-term follow-up of this study shows that adjuvant PCV chemotherapy 
given after radiotherapy improves overall survival (OS) in this tumor type (2). Molecu-
lar analysis has shown that in particular patients in which the tumor has a combined 
deletion of the 1p and 19q chromosomal arms (1p/19q co-deleted tumors) appeared 
to benefit from the addition of PCV treatment. A trial with similar inclusion criteria and 
treatment protocol, RTOG 9402, showed comparable results: patients with oligodendro-
glioma who harbor tumors with a 1p/19q co-deletion showed a benefit from neoadju-
vant PCV chemotherapy (3, 4). Combined, these trials have changed the standard of care 
for 1p/19q co-deleted tumors.
Results from both trials also indicate that a subset of patients benefit from (neo-) 
adjuvant PCV even though the tumor has retained 1p and/or 19q. In search for markers 
that identify those responsive patients, post hoc analysis on material from the EORTC 
26951 trial has shown that IDH1 mutational status and MGMT promoter methylation 
may be correlated to increased benefit to adjuvant PCV chemotherapy (5, 6). Statistical 
tests for interaction remained however negative, perhaps due to the relatively small 
number of patients of whom material could be analyzed. Similarly, gene expression 
profiling showed that tumors assigned to “intrinsic glioma subtype-9” (IGS-9, containing 
a high percentage of tumors with 1p/19q codeletion) showed benefit from adjuvant 
PCV chemotherapy (7). However, tumors assigned to IGS-17 (of which the majority had 
retained 1p and/or 19q) also showed a trend toward benefit from adjuvant PCV. These 
findings suggest there may be alternative molecular factors that predict benefit from 
adjuvant PCV chemotherapy.
In 2011, we have reported on a study in which genome-wide methylation profiling 
was conducted on snap-frozen tissue samples of patients included in the EORTC 26951 
trial. Similar to other studies, we found a strong correlation between a genome-wide hy-
permethylation phenotype (“CIMP”) and survival (8–11). However, preliminary analysis 
also indicated that CIMP status may be predictive for response to PCV chemotherapy. 
Unfortunately, the number of samples derived from the EORTC 26951 trial was too small 
(n = 50) to draw firm conclusions. At the time, analysis of additional samples was dif-
ficult as remaining samples were all fixed in formalin and embedded in paraffin (FFPE). 
However, recent technological advances suggest that FFPE tissues can be now used 
for genome-wide methylation analysis which increases the number of EORTC 26951 
samples available for methylation profiling.
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Apart from the potential predictive value of CIMP status, methylation of the MGMT 
promoter has been established as a predictive marker for outcome to chemo-irradiation 
with temozolomide in gliomas (12–14). In patients treated within EORTC 26951, we 
were unable to establish such an association between MGMT promoter methylation and 
benefit from adjuvant PCV chemotherapy (6). However, the assay used for our study 
(MS-MLPA, methylation-specific multiplex ligation-dependent probe amplification) 
interrogated different CpG sites than the assay used for the studies whereby MGMT 
promoter methylation status predicted benefit from chemotherapy (MS-PCR). Two 
regions within the MGMT promoter are correlated with mRNA expression levels, DMR1 
and DMR2, of which the latter is interrogated by MS-PCR (15). Recently, a study identified 
2 CpG sites that are correlated to MGMT RNA expression levels and patient survival (16). 
These CpGs are located on the Humanmethylation 27 and 450 arrays. These CpG sites 
lie within DMR1 and DMR2 and are not assessed by the MS-MLPA assay that we used to 
assess MGMT promoter methylation. A prediction model, MGMT-STP27, was generated 
to determine the MGMT promoter methylation status from the methylation data. We 
used this model as an alternative method to assess MGMT promoter methylation and 
compared it with our MS-MLPA findings.
MaTERIaLs aNd METhods
Patient samples
Patients were considered eligible in the EORTC 26951, if they had been diagnosed by the 
local pathologist with an AOD or an AOA according to the 1993 WHO classification. De-
tails of the eligibility criteria and the consolidated standards on reporting trials (Consort) 
flow diagram have been described previously (1). All samples that could be retrieved 
from this study were included (n = 115). A central pathology review was conducted on 
345 of 368 samples, 113 of 115 for samples used in present study. The 2 cases were 
omitted in the multivariate analysis that included review diagnosis as factor. All analyses 
using histologic diagnosis made use of the review diagnosis. Patient/sample characteris-
tics are detailed in Supplementary Table S1. Analysis of 1p/19qLOH, EGFR amplification, 
IDH1 mutations (as determined by direct sequencing of the c.395G mutation hotspot), 
and MGMT promoter methylation as assessed by MLPA on EORTC 26951 samples were 
described previously (1, 6, 17–19). Areas with high tumor content (>70%–80%) were 
highlighted by the pathologist (J.M. Kros) before conducting the IDH1 mutation analysis.
Six additional samples were collected from the Erasmus MC brain tumor tissue bank 
to test the performance of Illumina 450 k beadchips. One part of these tumors was fixed 
in formalin and embedded in paraffin, the other was snap frozen and stored at −80°C. 
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Patients provided written informed consent according to national and local regulations 
for the clinical study and correlative tissue studies.
Nucleic acid isolation and array hybridization
For FF tissues, gDNA was isolated from 5 to 40 cryostat sections of 40-μm thickness us-
ing the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s instructions. For 
FFPE tissue, gDNA was isolated from 8 to 10 sections of 10-μm thickness from paraffin 
blocks using the QIAamp FFPE DNA Kit. Methylation profiling was conducted using 
1 μg of gDNA which was subjected to bisulfite modification using the EZ DNA Meth-
ylation Kit (Zymo Research Company). Bisulfite-converted DNA was then hybridized to 
Illumina Infinium HumanMethylation 27 arrays (Illumina) by Service XS or to Infinium 
HumanMethylation 450 arrays (Illumina) run by ArosAB according to standard Illumina 
protocols. Data from 50 Infinium HumanMethylation 27 arrays samples were previously 
reported (11). All array data is available via the NCBI GEO datasets, accession number 
GSE48462. Infinium HumanMethylation 27 arrays interrogate 27,578 CpG sites across 
14,476 genes; the 450 arrays interrogate >485.000 CpG sites and contain most, but 
not all, of 27 k array content. The 450 k array contains 1,432 of 1,503 probesets used to 
determine CIMP status.
statistical analysis
Samples were assigned to either the CIMP+ or CIMP−subtype using ClusterRepro (an 
R package) based on the nearest centroid as described previously (20) according to 
the 1,503 CpGs described by the TCGA (10). The MGMT promoter methylation status 
(MGMT-STP27) was extracted from 2 CpG sites on the methylation array (cg12434587 
and cg12981137) as described (16). Differences between the Kaplan–Meier survival 
curves were calculated by the log-rank (Mantel–Cox) test using GraphPad Prism version 
5.00 for Windows, GraphPad Software. Comparisons between frequencies were calcu-
lated by the Fisher exact test in which P < 0.05 was considered to indicate significant 
differences. Progression-free survival (PFS) and overall survival (OS) were computed 
from randomization to date of event (progression and/or death) or censored at the date 
of last visit. To assess interfactor relationship, we used the well-established Spearman 
correlation coefficient (SCC) which provided for binary and ordinal factors the same 
measures of association as the phi coefficient. With the available sample size, clinically 
relevant coefficient (SCC ≥ 0.4) all had a significance lower than a conservative threshold 
of 1% (P < 0.01). The log-rank test for interaction was used to compare treatment effect 
in different molecular subsets. Significance analysis of microarrays (SAM) was conducted 
using SAMR, an R package, making use of censored survival outcome (21, 22). M-values 
of methylation were used for SAM analysis (23); CpGs located on the X or Y chromo-
somes were removed from all analysis. The variance inflation factor (VIF) was assessed 
46 Chapter 2
to determine the severity of multicolinearity between factors. For a factor, VIF = 4 (√4 = 
2) means that the SE of the coefficient of that factor is 2 times as large as it would be if 
it was uncorrelated to other factors. A VIF bigger than 2 is considered as large. Pathway 
analysis was conducted using IPA (Ingenuity Systems).
REsuLTs
Evaluation of the suitability of ffPE material for genome-wide methylation 
profiling
Most clinical trial samples are fixed in formalin and embedded in paraffin. Our first experi-
ments therefore evaluated the suitability of FFPE material for genome-wide methylation 
profiling. For this, we generated methylation profiles of 6 glioma samples, using 3 to 5 
replicates per sample. Replicates included (i) fresh-frozen (FF) samples (n = 4), (ii) FFPE 
of sections cut from a paraffin block (n = 6), (iii) FFPE of sections that were scraped from 
microscope slides to allow selecting for the area with highest tumor density (n = 6), (iv) a 
technical replicate of ii (n = 3), and (v) technical replicates of iii (n= 4). The time in paraffin 
of these samples was between 15 and 17 years.
A first evaluation showed that the signal intensities of the methylated and unmethyl-
ated probes of the array were higher in the FF samples than in the FFPE samples (6,882 
± 931 vs. 3,946 ± 1,438, P = 0.002; Supplementary Figure S1). Within the FFPE samples, 
scraped sections showed a significantly lower intensity than the whole FFPE sections 
(2,797 ± 962 vs. 5,096 ± 672, P < 0.001). Despite of these differences in signal intensities, 
there was no obvious difference between the different tissue sources in the beta values 
[methylated/(methylated + unmethylated), Supplementary Figure S1). Indeed, repro-
ducibility between the beta values of technical replicates was high: R2 = 0.987 ± 0.009 
(range, 0.969–0.994). Reproducibility between the beta values of whole tissue sections 
and scraped microscope slides was also high: R2 = 0.976 ± 0.012 (range, 0.960–0.985), 
which indicates that the enrichment for areas with high tumor content only marginally 
influences results in these samples.
When comparing the beta values of the FF samples with those of the FFPE samples, 
we also observed a high correlation between the replicates R2 = 0.961 ± 0.023 (range, 
0.919–0.987) when using all the 480 k CpG sites. This is remarkably high, especially when 
considering the time samples were stored in paraffin (15–17 years). This long storage 
time therefore does not significantly compromise on the performance of the platform. 
The high correlation between all replicates is also shown in an unsupervised clustering 
analysis conducted on the 2,000 most variable CpG sites in which samples from the 
same replicate clustered closely together (Figure 1). These data show that the Illumina 
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humanmethylation450 platform can be used to study CpG methylation on both FF and 
FFPE samples.
Previous methylation data on EORTC 26951 samples were generated using the Hu-
manMethylation27 beadchip. To determine whether the methylation array used for FFPE 
profi ling (HumanMethylation450) is comparable to the HumanMethylation27 beadchip, 
we analyzed 48 FFPE samples on both platforms. A high sample correlation in all samples 
across the 2 array types was observed when using the beta values of probesets that 
figure 1. 
485 98137138 490 568sample
FF/FFPE
slide/block
TR
CIMP- CIMP+
Hierarchical clustering of methylation profi les highlights similarity between FF and FFPE replicates from the 
same sample. Methylation profi les of 6 glioma samples were generated, labels for each sample are color 
coded below the plots. Replicates included (i) FF samples (n = 4), (ii) FFPE of sections cut from a paraffi  n 
block (n = 6), (iii) FFPE of sections that were scraped from microscope slides to allow selecting for the area 
with highest tumor density (n = 6), (iv) a technical replicate of ii (n = 3), and (v) technical replicates of iii (n 
= 4). The time in paraffi  n of these samples was between 15 and 17 years. The 2,000 most variable CpGs per 
sample are clustered with red corresponding to high M-values (methylated) and blue to low Beta-values 
(unmethylated). Hierarchical clustering of these 2,000 most variable CpG sites shows that the replicates 
from the same sample cluster together regardless of tissue origin (FF or FFPE) or whether FFPE samples 
were derived from tissue blocks (b) or scraped from tissue sections (s). TR, technical replicate. 
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are overlapping on both platforms (n = 25,978), R2 = 0.960 ± 0.020 (range, 0.854–0.982). 
These data show that the performance of the HumanMethylation450 beadchip is similar 
to the HumanMethylation27 beadchip.
We then conducted methylation profiling on 66 samples of the EORTC 26951 trial. 
Of these, 8 were FF and run on HumanMethylation27 beadchips, 59 were FFPE and run 
on HumanMethylation450 beadchips. Data were combined with 50 samples that were 
analyzed previously using FF samples on HumanMethylation27 beadchips (11). Data 
are available via NCBI GEO datasets, GSE48462. Samples 21 and 224 were run on both 
platforms, data from the HumanMethylation 450 beadchips for these two samples were 
used in the analysis. This sample cohort did not differ from the entire EORTC patient 
cohort with respect to age, sex, performance status, diagnosis, tumor location, IDH1 
mutation status, 1p/19q codeletion status, EGFR amplification, or MGMT promoter 
methylation status as assessed by MLPA (Supplementary Table S2). Our patient cohort 
however contained fewer biopsies and more total resections (P = 0.005). In addition, the 
treatment effect of patients included in this study was larger than the treatment effect 
of patients not included (Supplementary Figure S2): Median OS of patients included in 
the RT and RT-PCV arm was 1.6 and 5.7 years, whereas in patients not included it was 3.5 
and 3.2 years. The correlation between MGMT-STP27 and MGMT-MLPA, CIMP, IDH1 muta-
tion, and 1p/19q codeletion were, although significant, modest in strength [Spearman 
correlation coefficient MGMT-MLPA = 0.56, (P < 0.0001; with CIMP 0.39 (P < 0.0001), with 
IDH1 0.42 (P < 0.0001), and with 1p/19q 0.29 (P = 0.002)].
cIMP and MGMT methylation status are predictive for benefit from PcV 
chemotherapy
Of the 115 samples that were profiled, 66 were CIMP+ and 49 CIMP−. The MGMT pro-
moter methylation status (MGMT-STP27) extracted from the genome-wide methylation 
data identified 88 of 115 samples with a methylated MGMT promoter and 27 of 115 with 
an unmethylated promoter. CIMP and MGMT-STP27 status were correlated: of the 66 
CIMP+ samples, 60 had a methylated MGMT promoter, 6 were unmethylated. Of the 49 
CIMP-samples, 28 had a methylated MGMT promoter, 21 were unmethylated. 1p/19q 
codeletion was identified in 29 of 111 samples. All of the 48 CIMP− had retained 1p/19q 
as did 34 of 63 CIMP+ samples. Twenty-six of 27 MGMT-STP27 unmethylated samples 
had retained 1p/19q as did 56 of 84 MGMT-STP27 methylated samples. Correlation of 
CIMP and MGMT-STP27 status with other molecular markers and associated survival 
data are shown in Supplementary Table S3.
Univariate analysis indicates that patients with CIMP+ tumors have a more favorable 
prognosis than CIMP− tumors (6.65 vs. 1.05 years for OS and 3.69 vs. 0.50 years for PFS; 
Table 1 and Figure 2). Similarly, MGMT-STP27 methylated samples have a more favorable 
prognosis than MGMT-STP27 unmethylated samples (3.8 vs. 1.06 years for OS and 1.86 
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vs. 0.65 years for PFS; Table 1 and Figure 3). Multivariate analysis indicates that CIMP and 
MGMT-STP27 status are prognostic factors for survival in the presence of clinical and 
histological parameters (age, sex, performance score, type of surgery, and review diag-
nosis, Table 1). They are no longer independent prognostic variables when all clinical and 
molecular parameters and histology are included in the analysis (Table 1). In all analyses, 
all factors except STP27 (max 1.6) had a large VIF (>2). A limitation of these multivariable 
analyses is a limited sample size (n = 115) and presence of severe multicolinearity which 
might explain why CIMP and STP27 lost significance in the “all factors” analyses.
When stratified for treatment, patients with CIMP+ tumors showed a clear benefit 
from adjuvant PCV chemotherapy, both for OS and PFS (Table 2, Figure 2). For example, 
the median OS of CIMP+ samples in the RT and RT-PCV arms was 3.47 and 9.51 years, 
respectively. For CIMP− tumors, there was no such benefit for OS, although there was 
a slight increase in PFS 0.68 vs. 0.47 years. These data show that CIMP-positive status is 
predictive, at least for OS, for benefit from adjuvant PCV in patients treated within EORTC 
26951. The interaction test, however, remained above the threshold of significance (P = 
0.07, Figure 4)
A more pronounced benefit from treatment was observed in MGMT-STP27 methylated 
samples (Figure 3): Median OS of MGMT-STP27 methylated samples in the RT and RT-PCV 
arms was 1.98 and 8.65 years, respectively. For PFS, it was 0.73 and 5.36 years. For MGMT-
STP27 unmethylated, there was no such benefit, neither for OS nor for PFS. MGMT-STP27 
status was highly significant in the interaction test (P = 0.003, Figure 4).
figure 2. 
CIMP status is prognostic for survival in samples of 
the EORTC 26951 clinical trial. Kaplan–Meier sur-
vival curves show that patients harboring CIMP+ 
tumors have a better prognosis than patients with 
CIMP− tumors. A, PFS. B, OS. C–F, CIMP status is 
predictive for benefit to adjuvant PCV chemother-
apy. Kaplan–Meier survival curves showing that 
patients harboring CIMP+ tumors benefit both 
in PFS (C) and in OS (D) following adjuvant PCV 
chemotherapy. Patients harboring CIMP− tumors 
show modest improvement in PFS (E) but not in 
OS (F) following adjuvant PCV chemotherapy. For 
all graphs: black lines indicate the CIMP+ samples, 
gray lines indicate the CIMP− samples. Dashed 
lines are RT only, uninterrupted lines RT-PCV.
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Identification of cpG sites associated with survival and response to treatment
SAM analysis identified a total of 13,852 CpG sites that are associated with survival when 
using the entire dataset. This large number of CpGs (approximately half of all probesets 
on the array) is related to the tumors’ CIMP status and is illustrative for the large differ-
ences between these 2 subtypes. SAM analysis also identified 13 probesets and 3,921 
probesets associated with survival in the CIMP− and in the CIMP+ subtype, respectively. 
Hierarchical clustering based on these CpGs identified 2 distinct subtypes that indeed 
correlated with survival in our dataset (Supplementary Figure S3).
We next aimed to identify CpG sites associated with benefit from treatment. For this, 
we first conducted SAM analysis to identify CpG sites associated with survival in the 
RT-PCV arm and then removed all CpGs that were associated with survival in the RT-
only arm. To increase stringency, SAM analysis on the RT-only arm was conducted used 
relaxed criteria [false discovery rate (fdr) cutoff of 0.05], whereas stringent criteria were 
used to identify CpGs in the RT-PCV arm (fdr cutoff of 0.001). Our analysis identified 
13,912 and 3,308 CpGs associated with survival in the RT and RT-PCV arms, respectively. 
Most of the 3,308 CpGs identified by analysis of the RT-PCV arm were also present in 
the 13,912 CpGs identified by analysis of the RT arm. However, 259 CpGs were uniquely 
associated with survival in the RT-PCV arm (Supplementary Table S4).
The strongest differentially methylated CpG site identified this way was cg12981137, 
a probeset that is 1 of the 2 CpGs used to determine the tumors’ MGMT-STP27 status. 
The top networks associated with the 259 CpGs associated with treatment response 
involve “lipid metabolism,” “cancer,” “cellular development,” and “cellular movement” as 
determined by Ingenuity Pathway Analysis.
figure 3.
MGMT-STP27 status is prognostic for survival in sam-
ples of the EORTC-26951 clinical trial. Kaplan–Meier 
survival curves show that patients harboring MGMT-
STP27 methylated tumors have a better prognosis 
than patients that with MGMT-STP27 unmethylated 
tumors. A, PFS. B, OS. C–F, MGMT-STP27 status is pre-
dictive for benefit to adjuvant PCV chemotherapy. 
Kaplan–Meier survival curves showing that patients 
harboring MGMT-STP27 methylated tumors benefit 
both in PFS (C) and in OS (D) following adjuvant PCV 
chemotherapy. Patients harboring MGMT-STP27 un-
methylated tumors do not show benefit from adju-
vant PCV chemotherapy both in PFS (E) and in OS (F). 
For all graphs: black lines indicate the MGMT-STP27 
methylated samples, gray lines indicate the MGMT-
STP27 unmethylated samples. Dashed lines are RT 
only, uninterrupted lines RT-PCV.
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dIscussIoN
In this study, we have conducted genome-wide methylation profiling on samples 
treated within EORTC study 26951 on adjuvant PCV chemotherapy in anaplastic oligo-
dendroglial tumors. Although the study was set up to further explore the predictive 
significance of CIMP status, the results show a more predictive value of MGMT promoter 
methylation status as calculated from the methylation array data. Our data expand on 
the predictive power of MGMT promoter methylation status by showing it not only pre-
dicts benefit from temozolomide chemotherapy in patients with glioblastoma (12–14) 
but also predicts benefit from PCV chemotherapy in patients with AOA and AOD. Of 
note, the MGMT-STP27 has thus far only been tested on snap-frozen tissue samples (16).
figure 4. 
Forest plots of relative risk of CIMP and MGMT-STP27 in the RT and RT-PCV treatment arms. The interaction 
test for CIMP status of borderline significance, P = 0.07, χ2 3.37, degrees of freedom (df ) = 1. For MGMT-
STP27, the interaction test was significant P = 0.003, χ2 8.93, df=1. 
Table 2. CIMP and MGMT-STP27 status predict benefit from adjuvant PCV treatment
Pfs os
RT RT-PcV hR (95% cI) P RT RT-PcV hR (95% cI) P
CIMP
Pos 1.84 8.2 0.34 (0.18–0.62) 0.0005 3.47 9.51 0.40 (0.22–0.74) 0.0033
Neg 0.47 0.68 0.54 (0.30–0.98) 0.042 1.84 1.06 0.88 (0.49–1.60) 0.67
0.73 5.36 0.30 (0.18–0.50) <0.0001 1.98 8.65 0.37 (0.23–0.61) 0.0001
Unmeth 0.62 0.65 0.95 (0.44–2.10) 0.91 1.32 0.96 1.61 (0.71–3.65) 0.26
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Interestingly, previous experiments on EORTC 26951 clinical trial material failed to 
identify a predictive effect of MGMT promoter methylation status. In the previous study, 
however, MGMT promoter methylation status was determined using MLPA which inter-
rogates a different set of CpG sites than MGMT-STP27 (16, 24). Indeed, the Spearman 
correlation between MS-MLPA and MGMT-STP27 was only 0.56. This confirms that differ-
ent CpG sites within the MGMT promoter have different predictive power for outcome to 
alkylating chemotherapy. Other studies that confirmed the predictive power of MGMT 
promoter methylation also examined CpG sites that are different from those examined 
by the MLPA assay (12–14, 25). For example, the NOA-08 study has validated the role of 
MGMT determination in newly diagnosed glioblastoma (14). In addition to examining 
different CpG sites, the previous OS analysis of the MS-MSLPA on MGMT promoter meth-
ylation was based on the outcome data of the 2006 report on EORTC 26951. With longer 
follow-up, a long-term benefit of adjuvant PCV chemotherapy has been established, in 
particular of the 1p1/9q co-deleted tumors.
Bady and colleagues have conducted an analysis of the best CpG sites to predict 
MGMT promoter methylation status on the Illumina Beadchip27 and 450 platforms (16). 
However, it is possible that other CpGs that lie within the MGMT promoter provide an 
even greater predictive power than those of MGMT-STP27. To determine this, a further 
detailed analysis of the MGMT promoter region needs to be conducted in which meth-
ylation on all CpGs, but especially those in DMR1 and DMR2, are correlated to patient 
outcome. Data should then be validated on material derived from an independent trial.
Our observation that CIMP+ tumors benefit from adjuvant PCV chemotherapy is in 
line with other data obtained in anaplastic oligodendrogliomas: 1p/19q codeleted 
tumors are virtually all CIMP+, and we and others have reported that anaplastic oligo-
dendrogliomas with 1p/19q codeletion benefit from (neo) adjuvant PCV (4, 19, 26; see 
also ref. 27). Finally, the gene expression subtypes in the EORTC 26951 trial that benefit 
from adjuvant PCV (IGS-9 and IGS-17) are also CIMP+ (7). 
CIMP status is also highly correlated with IDH1 mutation status (Spearman correlation, 
ρ = 0.77), although 14/60 CIMP+ tumors are IDH1 wild-type. Recent evidence indicates 
that the hypermethylated phenotype is caused by metabolic changes due to mutations 
in the IDH1 gene (28–30). Previous analyses on EORTC 26951 trial material also showed 
an association between IDH1 mutations and treatment response. However, impact on 
outcome to PCV from both IDH1 mutation status and CIMP status remained nonsignifi-
cant in tests for interaction (5, 11). Apart from the present observation that CIMP status 
is predictive for benefit from adjuvant PCV chemotherapy, we also show that CIMP status 
is prognostic for survival. These data have been corroborated in other studies (8, 10, 11).
The 14 samples in our study that were IDH1 wt but CIMP+ may be the result of assay 
sensitivity (either in the determination of IDH1 or CIMP status), presence of other muta-
tions producing R-2-hydroxyglutarate [either rare mutations in IDH1 (31) or mutations in 
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IDH2] or a true positive finding that there are indeed CIMP+ tumors that are IDH1 wt. It 
should be noted that other groups have also identified CIMP+ tumors that are IDH1 wt. 
For example, in their original manuscript, the TCGA has identified 2 of 12 CIMP+ tumors 
that are IDH1 wt (10). This ratio of CIMP+ but IDH1 wt tumors is highly similar to that 
found in present study (14 of 63 or 22%).
Exploratory analysis of our dataset identified a set of CpGs that are associated with 
benefit from adjuvant PCV chemotherapy. One of the CpG sites identified by our analysis 
was cg12981137 which was the strongest candidate indentified by this analysis. This 
probeset is located within the MGMT promoter region and is a part of the previously 
defined MGMT-STP27 2 CpG site predictor profile of response to chemotherapy in glio-
blastoma. The second CpG of the MGMT-STP27 predictor was associated with survival in 
both treatment arms and therefore was not specific for OS benefit after RT-PCV. For all of 
the identified 259 CpGs associated with treatment response, it was always the methyl-
ated form that was associated with benefit from treatment.
One limitation of our study is that we were only able to analyze a subset of patients 
treated within EORTC 26951, although most characteristics of samples included versus 
those not included are similar. However, treatment effect of patients included is larger 
than patients not included (Supplementary Figure S2). Also, our sample cohort is rela-
tively modest in size (115) and our analysis is post hoc (retrospective testing). Our results 
therefore require validation in an additional independent cohort to firmly establish the 
predictive effect of CIMP status, MGMT-STP27 status, and the CpGs associated with treat-
ment response.
The practical consequence of our study is that the MGMT promoter methylation status 
needs to be determined in AOD. At present, there are different techniques available that 
determine the methylation status, and several of these are also currently being used 
in routine diagnostics. However, as some methylation sites within the MGMT promoter 
region have less predictive power than others, care should be taken to ensure that the 
correct CpG sites are interrogated. The use of Illumina beadchips as a diagnostic tool 
may be practically difficult to implement but this technique does offer the advantage 
that additional markers (such as CIMP status) may be added to the predictive (or 
prognostic) profile. In addition, methylation arrays can also be used to determine gross 
genomic changes such as 1p19q LOH. If the transition of glioma diagnostics toward 
more molecular-based diagnosis continues, these types of platforms may be rational.
In summary, we confirm, on clinical trial samples and using FFPE material, that CIMP 
status is prognostic for overall survival in the EORTC 26951 clinical trial. Although CIMP 
status is correlated to benefit to PCV chemotherapy, our data show a significant predic-
tive effect of the MGMT-STP27 status, although validation on an independent dataset is 
warranted. As only the MGMT-STP27 methylated samples show benefit from PCV, MGMT-
STP27 could be used to guide treatment decisions in this tumor type.
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absTRacT
The results from the randomized phase II BELOB trial provided evidence for a potential 
benefit of bevacizumab (beva; a humanized monoclonal antibody against circulating 
VEGF-A) when added to CCNU chemotherapy in recurrent GBM patients. In this study, 
we have performed gene expression profiling (DASL and RNA-seq) on formalin fixed, 
paraffin embedded (FFPE) tumor material from patients treated within the BELOB trial 
to identify recurrent GBM patients who benefit most from combined beva/CCNU treat-
ment. We first extensively validate the use of FFPE tissues for expression profiling on 
both DASL and RNA-seq. Our data show that tumors assigned to IGS-18 or ‘classical’ 
GBMs show a significant benefit in progression free survival (PFS) and a trend towards 
benefit in overall survival (OS) from beva+CCNU treatment; other subtypes do not show 
such benefit. In particular, expression of FMO4 and OSBPL3 were associated with treat-
ment response. All molecular glioma subtypes are evenly distributed along the different 
study arms and the improved outcome in the beva/CCNU arm therefore is not explained 
by an uneven distribution of prognostically favorable subtypes. Analysis of RNA-seq 
data highlighted genetic changes, including mutations, gene fusions (and identifica-
tion of the exact genomic breakpoint), and copy number changes (albeit with limited 
resolution) within this well-defined cohort of tumors. When validated in an independent 
dataset, the predictive markers identified in this study will allow selection of recurrent 
GBM patients that benefit from beva+CCNU treatment.
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INTRoducTIoN
Glioblastomas (GBMs) are the most common and aggressive type of glial brain tumors 
(1). The current standard of care for GBM patients includes surgical resection followed 
by combined chemo-irradiation with temozolomide (2). However, GBMs invariably re-
lapse and when this progression occurs, treatment options are limited. Nitrosoureas (in 
particular lomustine and carmustine), retreatment with (dose intense) temozolomide, 
re-irradiation, and re-resection are treatments that are often employed but have limited 
activity (3). Progression-free survival of recurrent GBM patients is in the range of 2-4 
months, and post-progression survival of about 6-8 months, with conventional chemo-
therapy (4).
GBMs are histologically characterized by endothelial proliferation and necrosis. At the 
molecular level, they are characterized by hypoxia induced- and HIF-1alfa dependent 
upregulation of Vascular Endothelial Growth Factor (VEGF) production by tumor cells, 
which subsequently induces new blood vessel formation (5). Because of the extensive 
endothelial proliferation that characterizes GBM, soon after the discovery of VEGF and 
its significance for the angiogenesis of tumor growth it has been hypothesized that GBM 
would provide a good target for anti-angiogenic treatments.
In spite of some initially promising results in uncontrolled trials however, recent data 
suggests that the effects of angiogenesis inhibition on overall survival (OS) is limited in 
both primary and recurrent GBM patients (6-9)_ENREF_6. For example, bevacizumab, 
a humanized monoclonal antibody against circulating VEGF, failed to demonstrate 
significant improvement of survival in newly diagnosed GBM patients in two large 
randomized phase III clinical trials (10, 11). Similarly, cediranib, a pan VEGFR inhibitor, 
did not improve outcome in recurrent GBM patients (12). Although the overall effects 
of angiogenesis inhibition may be disappointing, it is possible that subsets of patients 
do obtain some clinical benefit (for examples in glioma see (13-16). For bevacizumab, 
gene expression analysis provided preliminary evidence of benefit in distinct molecular 
subtypes of GBMs (17, 18).
Recently, results were reported for the BELOB trial, a trial from the Dutch Neuro- On-
cology Group (LWNO), in which patients were randomly assigned to treatment with 
lomustine (CCNU), bevacizumab (beva) or a combination of CCNU with beva (beva/
CCNU) (19). The trial results were intriguing as they indicate a potential survival benefit 
of beva/CCNU in recurrent GBM patients. In this study, we have performed gene expres-
sion profiling and RNA-sequencing on tumor samples derived from patients treated 
within the BELOB trial to identify recurrent GBM patients who benefit from combined 
beva/CCNU treatment. Our results show that of the different molecular subtypes of GBM 
(20, 21) ‘classical’ GBMs or those assigned to IGS-18 showed a trend towards benefit from 
treatment; other subtypes did not show such benefit. When validated in an independent 
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dataset, our data will allow selection of recurrent GBM patients that benefit from beva/
CCNU combination treatment.
MaTERIaLs aNd METhods
Patients were eligible for the BELOB trial if they were ≥18 years and had a first recurrence 
of GBM after temozolomide and radiotherapy treatment. Details of the study have been 
described previously (19). We also selected 37 paired FF-FFPE samples from the Erasmus 
University Medical Center glioma tumor archive, with FF and the FFPE samples taken as 
parallel biopsies from the same tumor. All of the FF–FFPE sample pairs were described 
previously to assess the performance of HuEx_1.0_St arrays (Affymetrix) (20, 22). Use 
of patient material was approved by the Institutional Review Board of the respective 
hospitals and patients provided written informed consent according to national and 
local regulations for the clinical study and correlative tissue studies.
Total RNA extraction, purification, and quantification from FF and FFPE material were 
reported previously (22). 250 ng of purified RNA was used for labeling and hybridization 
on DASL beadchips (run by Service XS, Leiden, the Netherlands); 500 ng was used for 
RNA-sequencing on an Illumina TruSeq and ~35-40 million 40 base paired end-reads 
were generated per sample. RNA-seq (n=96) was run by Expression Analysis (Durham, 
NC). DNA extraction was performed using the Allprep FFPE DNA/RNA FFPE kit (Qiagen, 
Venlo, the Netherlands) according to the manufacturers’ instructions. RNA expres-
sion profiles were then assigned to one of six intrinsic molecular subtypes of glioma 
(omitting IGS-0), or to one of four glioma subtypes as defined by the TCGA, using the 
ClusterRepro R package (http://crantastic.org/packages/clusterRepro) (23). Expression 
data is available at the NCBI Geo datasets, accession number GSE72951. Gene expres-
sion levels (Ref-seq genes) were extracted from the RNA-seq data using featureCounts 
(24), after alignment on hg19 with Tophat2 (25) of clipped/trimmed reads as provided 
by the manufacturer. VarScan 2 was used to identify SNVs and indels in the RNA-seq 
data (26-28), Annovar was used to annotate the SNVs (29). Candidate SNVs were filtered 
for SNVs that are present in the 1000 genomes database, and for changes that would 
result in a change in the primary protein sequence. We further focused on those that are 
either absent from dbSNP138 or are present in the COSMIC database (30, 31). ANKRD36 
was removed from this analysis: 497 mutations in 94 samples were identified in this 
gene, which is likely due to misalignment of homologous and/or non-refseq genes (e.g. 
ANKRD36B or FLJ54441). Candiate fusion genes were detected using ChimeraScan V0.4.5 
on hg19 (32). RT-PCR was used to confirm fusion candidates, Sanger sequencing was 
performed to confirm genetic changes.
Identification of recurrent GBM patients who may benefit from beva+CCNU 65
Differences between the Kaplan-Meier survival curves were calculated using the 
log- rank (Mantel-Cox) test using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA). For all analysis, OS and PFS were calculated from point of first 
recurrence. The significance of prognostic factors was determined with a multivariate 
analysis using Cox regression. In this analysis treatment was coded as 1. Beva/CCNU, 
2. CCNU and 3. Beva. Comparisons between frequencies were assessed by the Fisher’s 
exact test or the chi square test (where indicated). SAM analysis was performed using 
SAMR, an R package. The SAM approach to identify genes associated with treatment 
response is similar to previously reported using methylation arrays (33). Pathway analy-
sis was performed using Ingenuity IPA (Qiagen, Venlo, the Netherlands) using genes 
differentially expressed between IGS-18 and all other subtypes at P<0.01 and > 2x fold 
change in expression level.
REsuLTs
dasL and RNa-seq performance on ffPE samples and sample assignment
As RNA isolated from samples that are fixed in formalin and embedded in paraffin (FFPE) 
is degraded, we first ran a series of tests to determine the suitability of using DASL 
arrays and RNA-seq on FFPE isolated RNA. In this analysis we compared performance 
of the two platforms between technical and biological replicates, and compared the 
performance between snap frozen and archival samples that were stored >15 years in 
paraffin. Results are highlighted in the supplementary data results figures S1-S3. Our ex-
periments demonstrate that both DASL beadchips and RNA-seq can be used to perform 
gene expression profiling and assignment to specific molecular subtypes using FFPE 
tissues, even when the tissues were stored up to 20 years in paraffin.
Molecular subtypes of glioma in bELob trial tumor samples
All available BELOB trial samples (114/152) were assigned to molecular subtypes as 
defined by ‘Gravendeel’ (IGS-9, 17, 18, 22 and 23) and ‘Verhaak’ (Proneural, Neural, Clas-
sical and Mesenchymal) (20, 21) (table 2). The patient characteristics of tumor samples 
included in the current study did not differ from the entire BELOB patient cohort with 
respect to age, sex, performance score, MGMT promoter methylation and survival (table 
1). Material was unavailable for the remaining 38 tumor samples. As can be expected, 
most samples were assigned to the prognostically unfavorable subtypes IGS-18 and IGS-
23; GBMs are often assigned to these molecular subtypes (supplementary table 3). Few 
samples were assigned to the prognostically favorable subtypes IGS-9 and IGS-17. All 
subtypes, including the prognostically favorable samples, were evenly distributed along 
the different study arms and the improved outcome in the Beva/CCNU arm therefore is 
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not explained by a skewed distribution of these samples. When samples were assigned 
according to the TCGA classification of GBMs, most samples are assigned to the TCGA 
‘Classical’ and ‘Mesenchymal’ subtypes and few to the ‘proneural’ and ‘neural’ subtypes 
(table 2). From the point of 1st recurrence, the timepoint used for all analysis in current 
manuscript, the survival (both OS and PFS) between molecular subtypes was not signifi-
cantly different Supplementary figure S4. 
Table 1. Patient data
current study
Patients from the bELob 
trial not included in
present study
P
N=114 N=38
Beva CCNU BC Beva CCNU BC 
35 (30) 37 (32) 43 (37) 15 (46) 9 (27) 9 (27)
N(%) N(%) N(%) N(%) N(%) N(%)
age, years
Median 58 57 57 58 56 57.5 0.25
Range 37-77 28-73 24-73 38-72 46-68 41-72
sex
Male 21 (60) 20 (54) 30 (70) 11 (73) 7 (70) 3 (33) 0.29
Female 14 (40) 17 (46) 13 (30) 4 (26) 3 (30) 6 (67)
Performance status
0 11 (31) 13 (35) 10 (23) 2 (13) 2 (20) 4 (44) 0.52
1 19 (54) 19 (51) 27 (63) 13 (87) 7 (70) 5 (56)
2 5 (14) 5 (13) 6 (14) 0 (0) 1 (10) 0 (0)
Idh1 mutation
Normal 31 (89) 32 (88) 38 (88) 7 (47) 7 (70) 4 (44) 0.73
Mutated 1 (3) 2 (6) 4 (9) 0 (0) 1 (10) 0 (0)
Missing 3 (9) 2 (6) 1 (2) 8 (53) 2 (20) 5 (56)
MGMT promoter
methylation
Unmethylated 18 (51) 18 (49) 24 (56) 6 (40) 3 (30) 2 (22) 0.91
Methylated 16 (46) 18 (49) 18 (42) 2 (13) 5 (50) 3 (33)
Missing/unvalid 1 (3) 1 (3) 1 (2) 7 (47) 2 (20) 4 (44)
Median survival (months)
Progression-free survival 3.0 1.9 4.1 2.7 1.4 7.9
Overall survival 8.3 7.9 10.8 5.9 6.9 13.6
Abbreviations: Beva: bevacizumab; CCNU: Lomustine; BC: Bevacizumab and CCNU; P<0.05 is considered a 
statistically significant between patients included vs not included
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Similar to previously reported, specific genetic changes segregate into distinct 
intrinsic subtypes (supplementary figure S5). For example, IDH1 mutations were pres-
ent in eight BELOB tumor samples (expression data are available for seven), and were 
identified predominantly in prognostically favorable subtypes IGS-9 (2/4, 50%), IGS-17 
(3/9, 33%) and at much lower frequency in IGS-18 (1/72) and IGS-23 (1/28) (P<0.001 IGS-
9+17 v. IGS-18+23). Similarly, IDH1 mutations were predominantly found in ‘proneural’ 
GBMs (3/8). EGFR amplification is a common event in IGS-18 and in ‘classical’ GBMs (20, 
34), and is associated with mRNA upregulation and with an accumulation of genetic 
changes in this locus (34). In the current dataset, samples assigned to either IGS-18 or 
‘classical’ GBMs indeed have a significantly higher expression of EGFR (14.2 v. 12.8 for 
IGS-18 v. any other subtype on DASL, P<0.001 students t-test; data are identical for ‘clas-
sical’ v. any other subtype). Samples assigned to IGS-18 (or ‘classical’ GBMs) also have a 
significantly higher frequency of genetic changes in the EGFR locus as determined by 
RNA-seq (31/47 in IGS-18 v. 5/29 in any of the other subtypes, P<0.001, Fisher exact test). 
Similar for ‘classical’ v. other GBMs: 34/51 v 2/24 (P<0.001). The assignment of tumors 
to specific molecular subtypes therefore corresponds to the histological diagnosis (i.e. 
predominantly prognostically poor subtypes) and to the type of genetic changes found 
(i.e. specific genetic changes segregate within defined molecular subtypes).
Response to treatment
The molecular subtypes of gliomas identified in BELOB tumor samples were then strati-
fied according to treatment arm. In this retrospective analysis, samples assigned to IGS-
18 showed a trend towards benefit from the combination of bevacizumab and CCNU 
(median OS 7.9, 8.3 and 11.9 months in the CCNU, beva and beva/CCNU arms respec-
tively P=0.09, figure 1). This trend was absent when grouping all samples not assigned 
to IGS-18 (median OS 10.1, 8.9 and 6.3 months in the CCNU, beva and beva/CCNU arms 
respectively P=0.85); too few samples assigned to IGS-9, IGS-17, IGS-22 or IGS-23 to as-
sess treatment response in individual subtypes. A significant benefit in progression free 
survival (PFS) was observed for tumor samples assigned to IGS-18: survival of samples 
Table 2. Sample assignment
Proneural Neural Classical Mesenchymal Total
IGS-0 1 3 0 0 4
IGS-9 2 0 0 0 2
IGS-17 2 4 1 0 7
IGS-18 1 1 68 0 70
IGS-22 2 0 1 0 3
IGS-23 0 1 7 19 27
Total 8 9 77 19 113
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assigned to IGS-18 was 1.4, 2.9 and 4.2 months in the CCNU, beva and beva/CCNU arms 
respectively (P=0.0004), for non-IGS-18 samples it was 2.8, 4.1 and 3.7 months (P=0.23, 
figure 1).
Analysis of subtypes defined by the TCGA showed similar results: ‘classical’ GBMs 
showed a trend towards improved survival from the combination of bevacizumab and 
CCNU (median OS 8.2, 8.3 and 11.9 months in the CCNU, Beva and Beva/CCNU arms 
respectively P=0.097, median PFS 1.7, 3.0 and 4.2 months, P=0.001, supplementary 
figure S6). This trend was absent when grouping all ‘non-classical’ GBMs (median OS 8.7, 
7.1 and 5.9 months in the CCNU, beva and beva/CCNU arms respectively P=0.90, median 
PFS 2.7, 3.0 and 3.7, P=0.29); too few samples were ‘mesenchymal’, ‘proneural’ or ‘neural’ 
to assess treatment response in individual subtypes. These data suggest that recurrent 
GBM patients whose tumors are assigned to IGS-18 or are ‘classical’ GBMs may benefit 
from the combination of bevacizumab and CCNU whereas tumors assigned to other 
subtypes do not show such benefit.
figure 1. 
Distinct molecular subtypes of GBM show a trend towards benefit from Beva/CCNU treatment. The molecu-
lar subtypes of glioma were stratified according to treatment arm. Tumors assigned to IGS-18 show a trend 
towards benefit from Beva/CCNU treatment in both OS (A) and PFS (B). Tumors assigned to other subtypes 
combined do not show such benefit (C and D). 
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We next aimed to identify genes and molecular pathways that were associated with 
treatment response on overall survival. We first performed SAM analysis and identified 
two genes (FMO4 and OSBPL3) that are associated with overall survival specifically in 
the beva/CCNU treatment arm (using a false discovery rate cutoff of 0.05). SAM analysis 
failed to identify genes associated with survival in the CCNU and beva monotherapy 
arms of this study. As the two genes are associated with survival only in the beva/CCNU 
treatment arm, these genes may be considered specifically associated with response to 
treatment (figure 2). Indeed, clustering samples based on FMO4 and OSBPL3 expression 
divided samples in two major subtypes (figure 2). Overall survival between the two sub-
types was similar for patients treated with either CCNU or beva monotherapy (median 
survival of 8.3 v. 8.5 and 6.1 v. 10.1 months for CCNU and beva monotherapy respectively, 
P=0.57). However, survival between the two subtypes significantly differed for patients 
treated with beva/CCNU (median survival of 6.1 v. 12.4 months, P<0.0001). There is no 
figure 2. 
SAM analysis identified two genes (FMO4 and OSBPL3) that are associated with overall survival specifically 
in the Beva/CCNU treatment arm. Unsupervised hierarchical clustering based on these two genes separates 
tumors in two major subtypes. Subsequent stratification of tumors by treatment shows that FMO4/OSBPL3 
expression predicts response in the Beva/CCNU arm (left) but not in the other (Beva or CCNU monotherapy) 
arms (right).
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difference in gene expression levels of these two genes between the different molecular 
subtypes (supplementary data figure s8).
Because tumors assigned to IGS-18 show a trend towards benefit from beva/CCNU, 
we also performed pathway analysis on genes differentially expressed between IGS-18 
and all other molecular subtypes. Pathway analysis was performed using our previously 
reported dataset containing snap frozen tumor samples (20). A total of 241 differentially 
expressed genes and seventeen differentially activated pathways were identified. Path-
ways included those that are involved in a.o. cellular assembly, cancer, cellular growth 
and proliferation. We then used the entire set of genes of each individual pathway (also 
including genes not differentially expressed between IGS-18 and other molecular sub-
types) to screen whether the pathway is associated with response to beva/CCNU treat-
ment. Four of these pathways were associated with response to beva/CCNU treatment, 
the other thirteen pathways showed little association (supplementary table 4, supple-
mentary figure S7a and b). Functions of the four pathways associated with response 
to beva/CCNU combination treatment were often overlapping and include functional 
descriptors such as ‘cellular assembly and organization’, ‘growth and proliferation’ and 
‘tissue/organ morphology’.
Univariate analysis highlighted that in BELOB samples, MGMT promoter methylation 
(P=0.01), IDH1 mutation status (P=0.04), treatment (P=0.04) and FMO4/OSBPL3 expres-
sion (P<0.0001) were factors significantly correlated with OS. It should be noted however 
that the study was not powered to perform comparative analysis. Multivariate analysis 
including these factors showed MGMT promoter methylation, treatment and FMO4/
OSBPL3 expression as independent prognostic factors associated with overall survival 
(table 3A; supplementary table 5). The interaction between FMO4/OSBPL3 expression 
and treatment was significant confirming the notion that high FMO4/OSBPL3 expression 
is associated with treatment response in the bev/CCNU arm. Factors associated with 
PFS in a univariate analysis were MGMT promoter methylation (P=0.004), IDH1 mutation 
status (P=0.017), performance status (P=0.013), intrinsic subtype (P=0.018), treatment 
(P=0.006) and FMO4/OSBPL3 expression (P=0.0004). Multivariate analysis including 
these factors showed MGMT promoter methylation, IDH1 mutation status and treat-
ment as independent prognostic factors associated with PFS (table 3B). The interaction 
between FMO4/OSBPL3 expression and treatment was also significant for PFS in this 
analysis confirming association of FMO4/OSBPL3 expression with bev/CCNU treatment.
In patients of the TCGA database that received bevacizumab at any time during the 
treatment, a non-significant tendency towards increased survival was observed in tu-
mors with high expression of FMO4 or OSBPL3 (strongest in GBMs assigned to IGS-18: 
median survival of 1.21 v 1.50 years for both FMO4 and OSBPL3, supplementary figure 
S9). High expression of FMO4 or OSBPL3 was not associated with increased survival in 
the entire TCGA GBM dataset. We should stress that these data should be interpreted 
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with caution: the number of patients receiving bevacizumab (and assigned to IGS-18) 
is small (n=18), patients did not receive uniform treatment, and bevacizumab may have 
been given at a time-point different from the BELOB study.
Mutations and structural rearrangements
Mutation analysis using RNA-seq data identified a total of 45 mutations in 13 genes (out 
of the 71 genes frequently mutated in GBMs (34).) in 78 BELOB trial samples (table 4). 
Genes include EGFR (n=29, with often multiple mutations in a single sample), PTEN (n=10 
of which 4 result in a premature stop codon), TP53 (n=4), and NF1 (n=2). The frequency 
of most mutations is slightly lower than previously reported (34) and can be explained 
because many genes are expressed at low levels, especially when one allele is lost as 
is the case in many tumor suppressor genes. In addition, homozygous deletions will 
not be identified by RNA-seq. However, a low frequency for several genes also reflects 
the high number of “classical” GBMs in our dataset: PIK3CA, PIK3R1 and TP53 mutations 
are common to “proneural” GBMs, NF1 mutations are common to “mesenchymal’ GBMs 
(21). The mutations per sample, along with the clinical data and molecular subtype are 
shown in figure 3. The type and frequency of mutations identified corresponds to those 
reported previously for GBMs, although RNA-seq is likely to underestimate the mutation 
frequencies in genes expressed at low level, particularly in tumor suppressor genes (34, 
35).
Table 3a. Multivariate analysis of factors associated with overall survival
Haz. Ratio Std Err. z P>|z| 95% Conf. Interval
MGMT 0.60 0.22 -2.35 0.019 0.39 0.92
IDH1 0.45 0.55 -1.46 0.144 0.15 1.32
Treatment 1.34E+07 4.03 4.07 0.000 4.95E+03 3.63E+10
FMO4/OSBPL3 0.79 0.12 -1.89 0.059 0.63 1.01
TRT * F/O 0.43 0.21 -4.09 0.000 0.28 0.64
Trt * F/O: interaction term treatment and FMO4/OSBPL3 expression
Table 3b. Multivariate analysis of factors associated with progression free survival
Haz. Ratio Std Err. z P>|z| 95% Conf. Interval
MGMT 0.55 0.22 -2.68 0.007 0.36 0.85
IDH1 0.31 0.56 -2.06 0.039 0.10 0.95
Performance 3.91 1.05 1.30 0.194 0.50 30.73
IGS-subtype 1.07 0.09 0.77 0.443 0.90 1.27
Treatment 1.05E+08 4.37 4.23 0.000 2.01E+04 5.45E+11
FMO4/OSBPL3 1.08 0.13 0.57 0.566 0.84 1.38
TRT * F/O 0.37 0.23 -4.36 0.000 0.24 0.58
Trt * F/O: interaction term treatment and FMO4/OSBPL3 expression
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We also used RNA-seq to identify (large) chromosomal losses: regions with chromo-
somal loss will be represented by RNA-seq as regions absent in heterozygous SNPs. Allele 
specific expression will also be reflected as a region absent in heterozygous SNPs (such 
as occurs in females on the X-chromosome), but this occurs a minority of genes only 
(36). Our algorithm was tested by comparing control samples of which SNP data was 
also present from snap frozen samples (see ref (37), Supplementary figure S10). The only 
frequent LOH observed was LOH of chromosome 10 and was observed at significantly 
higher frequency in samples assigned to IGS-18 (34/43, 79%) compared to IGS-23 (6/16, 
38%) or other molecular subtypes (1/9, 11%, P<0.001 chi- square test). 
ChimeraScan identified a total of 8879 candidate fusion genes (range 12-209). Within 
the technical and biological replicates, the overlap in identified candidates was low (39.6 
± 9.7%) but improved significantly when additional filters were applied (at least ten 
reads covering the breakpoint of which at least two chimeric reads), to 95±9.2%. When 
applying these filters to the entire dataset, and removing falsely called fusion transcripts 
due to alternative splicing events and those that occur in repetitive sequences, 28 can-
didate fusion genes remained (Supplementary table 6). These fusion candidates include 
the known fusion genes FGFR3-TACC (n=2) and EGFR-SEPT14 (n=2) (38-40)_ENREF_28. 
WIF1 and VSTM2A were identified as a novel fusion partner of EGFR.
Table 4. Frequency of mutations identified by RNA-seq
Gene mutated samples (n) frequency (%) Brennan frequency (%)
EGFR * 29 37.2 32.6
PTEN 10 13.0 32
TP53 5 6.5 34.4
NF1 ** 2 3.8 13.7
IDH1 2 2.6 5.2
RPL5 2 2.6 2.7
ATRX 2 2.6 5.8
PIK3R1 1 1.3 11.7
ZNF844 1 1.3 2.1
RB1 1 1.3 9.3
ABCC9 1 1.3 4.8
PDGFRA 2 2.6 4.5
SCN9A 1 1.3 3.8
ANKRD36 0 0.0 1.7
PIK3CA 0 0.0 12
SEMA3C 0 0.0 3.8
CD3EAP 0 0.0 1
CARD6 0 0.0 2.4
* for many mutations in EGFR, the frequency was below the minimal allele frequency used by varscan. For this 
analysis we also included hotspot mutations at low frequency. ** one tumor harboured two mutations in NF1. 
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figure 3. 
Summary of molecular and clinical parameters of patients with available RNA-seq data. Top rows depict 
molecular subtypes according to Gravendeel et al(20) (DASL expression and RNA seq) and according to 
Verhaak et al (21). MGMT promoter methylation was reported previously (19). LOH of Chr 10 was extracted 
from RNA-seq data based on monoallelic expression. Top boxed area depicts genetic changes found by 
RNA-seq. The specific genetic changes in EGFR is depicted in the lower boxed region and includes muta-
tions, intragenic deletions and fusion genes.
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All remaining fusion genes were unique events though some fusion partners (NUP107, 
VOPP1, GRB10, LANCL2, MLLT3 and VSTM2A) were identified in two samples. Fusion 
genes are incorporated, alongside with clinical and other molecular data in figure 3. 
Fusion genes involving NUP107 surround the MDM2 locus, and it is possible they occur 
secondary to a high copy amplification of this locus (both samples express high levels 
of MDM2). There are four samples with NUP107 fusion genes in the TCGA dataset, all 
of which have high copy MDM2 amplification (34). By analogy, both PSPH and VOPP1 
are located close to the EGFR locus and, in the TCGA dataset, fusions involving PSPH or 
VOPP1 are either associated with EGFR amplification or are direct fusion partner of EGFR.
analysis of intronic reads can identify the genomic breakpoint of fusion genes 
Sequencing of total RNA results in a large proportion of intronic reads (41). This is likely 
caused by the use of random primers for cDNA synthesis; in random primed cDNA synthe-
sis both the mature and unspliced mRNAs are converted into cDNA. In general, introns are 
spliced out only after transcription of the entire intron. Therefore, on a population level, 
the 5’ end of an intron will have a higher read-depth than the 3’ end (41). This is particularly 
visible in transcripts with long introns (42), as the half-life of an intron is determined by 
its length and by the rate of RNA polymerase II transcription, ~3.5-4 kb/hr (43, 44). Of 
note, we have observed exceptions to this rule, arguing for intra-intronic splicing events 
(see supplementary figure S11 for some examples). Additional calculations on the rate of 
transcription and the level of expression is depicted in Supplementary figure S12.
We hypothesized that the presence of the pre-mRNA transcripts can be used to identify 
intronic genomic breakpoints of fusion genes: where in intact introns there is a relatively 
stable coverage of pre-mRNA levels, the levels of pre-mRNA may suddenly change at the 
exact genomic breakpoint of a fusion gene. Indeed, such sudden decreases/increases 
of pre-mRNA levels are often present in the introns of the fusion genes identified by 
ChimeraScan. PCR using primers spanning the putative breakpoint confirmed the pres-
ence and location of the genomic break (supplementary figure S13).
dIscussIoN
In this study we have performed gene expression profiling and RNA-sequencing on 
tumor material derived from patients treated within the BELOB trial in order to identify 
recurrent GBM patients who benefit from combined CCNU and bevacizumab treatment. 
Our results indicate that patients with a specific molecular subtype of glioma, IGS-18 or 
‘classical GBMs’, may show more benefit from beva/CCNU treatment. In particular, the 
expression of FMO4 and OSBPL3 are correlated with benefit from this combination treat-
ment. It should be noted however that our data analysis is post-hoc and confirmation in 
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an independent dataset is therefore required. The in-depth analysis of the transcriptome 
by RNA-seq also highlighted genetic changes (mutations, indels, gene fusions (includ-
ing identification of the exact genomic breakpoint) and copy number changes (albeit 
with limited resolution)) within this well-defined cohort of tumors.
Recently, data were reported on two large randomized phase III clinical trials that 
investigated the role of the addition of bevacizumab to temozolomide chemo- radio-
therapy in newly diagnosed GBM patients (10, 11). Unfortunately, the results show that 
the combination treatment did not result in an increased overall survival of patients. 
Subsequent translational research however, did identify subgroups of patients that 
showed benefit from beva + temozolomide treatment (17, 18). For example, Sulman 
et al. provided evidence, in the RTOG 0825 study, that ‘mesenchymal’ GBMs performed 
particularly poor on the combination treatment (18). Although these data were gener-
ated on newly diagnosed GBMs, our data on recurrent GBMs largely corroborate these 
findings: no trend towards treatment benefit was identified in ‘non-classical’ GBMs 
(most of which were mesenchymal tumors, though numbers are too small to draw firm 
conclusions). Recently, Phillips et al, in the AvaGlio study, demonstrated that G-CIMP- 
‘proneural’ GBMs benefitted from beva + temozolomide (17). Our dataset however, 
contains very few ‘proneural’ GBMs, which may be related to the observation that these 
tumors have the worst prognosis of all GBM subtypes and may simply not qualify for 
second line treatment (34). Based on data provided in current manuscript, it would be 
interesting to see whether in those studies tumors assigned to IGS-18 also show benefit 
from the addition of bevacizumab to chemotherapy.
Of note, in a recent retrospective analysis, patients with tumors assigned to IGS-18 
or classical GBMs had worse outcome compared to those assigned to IGS-22/23 when 
treatment with a combination of beva and irrinotecan (45).
SAM analysis identified two genes that were associated with survival specifically in the 
beva/CCNU combination arm. Flavin-containing monooxygenase 4 (FMO4) is a protein 
that catalyzes the NADPH-dependent oxygenation of drugs, pesticides and xenobiot-
ics (46). FMO4 is part of a protein family (FMO1-5) that, after cytochrome P450, is the 
second largest protein family involved in drug metabolism. FMO oxidation increases the 
polarity of (nitrogen-containing) substrates, which aids excretion and detoxification, but 
may also catalyze drugs into more active forms. Since FMO4 expression is involved in 
drug metabolism and is associated with survival in the beva+CCNU arm, it is possible 
that FMO4 expression may render tumors more sensitive to CCNU treatment (when in 
combination with beva).
OSBPL3 is one of the twelve members of the oxysterol binding protein (OSBP) related 
protein (ORP) family that play a role in lipid metabolism, vesicle trafficking and cell 
signaling (47). OSBPL3 binds to the phosphoinositides PIP2 and PIP3 and can interact 
with the small GTPase R-RAS (48, 49). OSBPL3 was shown to play a role in the regulation 
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of the actin cytoskeleton and cellular adhesion (49). Since a set of tumors respond to 
bevacizumab by increased migration/invasion and vessel co-option (50, 51) and VEGF 
directly inhibits glioma invasion (52), it is possible that increased OSBPL3 expression 
increases cellular adhesion and so reduces the migratory capacity of tumor cells. Per-
haps a combination of altered migration and drug metabolism renders tumors in the 
beva+CCNU arm more sensitive to this treatment.
One of the peculiarities of our dataset is that it contained an overrepresentation of 
tumors assigned to IGS-18 or ‘classical’ GBMs where in general, GBMs are roughly equally 
distributed across the various molecular subtypes (20, 21, 53, 54). We are confident how-
ever of the molecular classification as described in current manuscript: there was a high 
correlation in tumor assignment between snap frozen and FFPE samples and between dif-
ferent methods (DASL and RNA-seq) and genetic changes in the EGFR locus (and 10q LOH) 
are a hallmark of IGS-18 or ‘classical’ GBMs and most tumors assigned to IGS-18 or ‘classical’ 
GBMs indeed harbor genetic changes in this gene. This segregation of genetic changes 
was also observed for IDH1. The higher frequency of tumors assigned to IGS-18 or ‘classi-
cal’ GBMs may reflect a sample bias of current study. However, in a study analyzing EGFR 
amplification in matched primary and recurrent tumors, we also find a high frequency of 
EGFR amplification at initial diagnosis (~70%, van den Bent et al., accepted for publication). 
It is therefore possible that (EGFR-amplified-) tumors assigned to IGS-18 are more prone 
to receiving re- treatment at tumor recurrence. For example, G-CIMP- proneural GBMs are 
selected against as they have poorest prognosis of all GBM subtypes (34).
A limitation of our study is the use of primary tumor tissue for classification, whereas 
the recurrent tumor was treated. In 2006, a study identifying three molecular subtypes 
of glioma included analysis of 26 (unselected) matched primary and recurrent tumor 
pairs (54). This study showed that at progression, gliomas shift from a proneural towards 
a mesenchymal subtype. However, it also demonstrated that 18/26 (70%) tumors remain 
in the same subtype (a similar retention of molecular subtype is observed when these 
tumors to molecular subtypes as defined by Gravendeel et al supplementary table 7). 
More specifically, within the eight tumors assigned to IGS-18 at initial diagnosis in this 
study, six remained in IGS-18 at tumor recurrence. A study performed by our group 
included seven repeat samples and both tumors assigned to IGS-18 at initial diagnosis 
remained in IGS-18 at tumor recurrence (20). Moreover, we have recently performed 
analysis of the EGFR locus in 55 uniformly treated primary recurrent tumor pairs (van 
den Bent et al., accepted for publication). EGFR amplification can be used as surrogate 
marker for IGS-18 tumors: retention of EGFR amplification status at tumor recurrence 
therefore is suggestive for retention of the intrinsic glioma subtype. The data from this 
study indicate that the EGFR status of the tumor remains similar at the point of recur-
rence in 47/55 matched tumor pairs. These studies suggest that in many tumors, the 
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molecular subtype largely remains identical at tumor progression (even though they 
may shift towards a more mesenchymal phenotype).
A second limitation of this study is that material was available for only a subset 
(114/152) of BELOB trial samples. Although we did not identify differences in patient 
characteristics of tumor samples included vs not included (table 1), the use of only a 
subset of patients may have introduced a sample bias.
Recurrent fusion genes identified in our dataset (FGFR3-TACC3 and EGFR-SEPT-14) were 
identified by others with similar frequencies (34, 38, 39, 55). A recent analysis identified the 
genomic landscape of fusion genes in 13 tumor types, including GBMs (40). Two identical 
fusion genes (LANCL2-SEPT14 and ZZEF1-ANKFY1) can be detected when overlaying the 
identified fusions in that study with those reported here. Based on the amplification status 
of MDM2 and EGFR and the fact that they are present as double minutes when amplified, 
we hypothesize fusions involving NUP017, PSPH or VOPP1 occur secondary to high copy 
gene amplification. If so, this implies that GBMs harbor few functional fusion genes.
Apart from the recurrent fusions, many of the 5’ and 3’ fusion partners were also identi-
fied by others (e.g. GRB10, LANCL2, MLLT3, ASCC3, VOPP1, TERT, VSTM2A, PSPH, NUP107 
and LEMD3), some of which are found at significant frequency (GRB10, NUP107 VOPP1, 
TERT, PSPH) (38-40, 55). One of the potentially functional fusions partner is TERT: TERT 
fusions can represent a method to increase telomerase activity, as alternative to the 
frequent TERT promoter mutations in GBMs (56). A total of 7 samples (of which 2 GBMs) 
were recently identified to contain TERT fusion genes. In all cases identified, TERT acted 
as the 3’ fusion partner, and all contained the telomerase transcriptase domain (tran-
scripts from exon 2 or 3 onwards) which argues against random occurrence the fusion.
Many of the reads identified by RNA-sequencing of FFPE isolated material mapped 
to intronic regions and represent pre-mRNA species. Similar to previously reported, our 
data shows that the 5’ end of an intron has a higher read-depth than the 3’ end, at least 
in large introns (41). The 5’-3’ decline in intronic reads is linear and is explained by a 
mechanism where introns are first entirely transcribed before being spliced out (41). 
However, in some genes have introns that are apparently spliced out before transcrip-
tion of the entire intron (i.e. intra-intronic splicing). Apart from a basic insight into the 
mechanism of RNA maturation, we here we show that intronic reads can be used to map 
genomic breakpoints of fusion genes.
In summary, our results show that tumors assigned to IGS-18 or ‘classical’ GBMs showed 
a significant benefit in PFS and a trend towards benefit in OS from beva+CCNU treat-
ment; other subtypes did not show such benefit. Expression of FMO4 and OSBPL3, genes 
involved in drug metabolism and cell signalling, regulation of the actin cytoskeleton and 
cellular adhesion were specifically associated with treatment response. When validated 
in an independent dataset, our data will allow selection of recurrent GBM patients that 
benefit from beva+CCNU treatment.
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absTRacT
background
Epidermal growth factor receptor (EGFR) is frequently mutated in various types of can-
cer. Although all oncogenic mutations are considered activating, different tumour types 
have different mutation spectra. It is possible that functional differences underlie this 
tumour-type specific mutation spectrum.
Methods
We have determined whether specific mutations in EGFR (EGFR, EGFRvIII and EGFR-L858R) 
have differences in binding partners, differences in downstream pathway activation 
(gene expression and phosphoproteins), and have functional consequences on cellular 
growth and migration.
Results
Using biotin pulldown and subsequent mass spectrometry we were able to detect 
mutation specific binding partners for EGFR. Differential binding was confirmed using a 
proximity ligation assay and/or Western Blot for the dedicator of cytokinesis 4 (DOCK4), 
UDP-glucose glycoprotein glucosyltransferase 1 (UGGT1), MYC binding protein 2 (MY-
CBP2) and Smoothelin (SMTN). We also demonstrate that each mutation induces the 
expression of a specific set of genes, and that each mutation is associated with specific 
phosphorylation patterns. Finally, we demonstrate using stably expressing cell lines 
that EGFRvIII and EGFRL858R display reduced growth and migration compared to EGFR 
wildtype expressing cells.
conclusion
Our results indicate that there are distinct functional differences between different 
EGFR mutations. The functional differences between different mutations argue for the 
development of mutation specific targeted therapies.
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INTRoducTIoN
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is a mem-
ber of the ERBB protein family and is localised on the cell membrane. The receptor is 
activated by members of the epidermal growth factor (EGF) family (a.o. EGF, amphiregu-
lin, TGF-a, HB-EGF and epiregulin) and binding of one such ligand results in receptor 
dimerisation which induces receptor phosphorylation, recruitment of adaptor proteins 
and subsequent activation of signal transduction cascades (1,2).
Somatic mutations in the EGFR gene are found in several types of cancer and the muta-
tion spectrum includes gene amplifications, gene-fusions, deletions in the extracellular 
domain (e.g. EGFRvIII; a deletion of exons 2–7), deletions in the intracellular domain (e.g. 
EGFRvV; a deletion of exons 25–28) and mutations affecting the tyrosine kinase domain 
(mainly exon 19 and codon L858) (3–5). These mutations result in a constitutively acti-
vated isoform of the protein and contribute to oncogenic transformation (5–8).
Although EGFR mutations are activating, there are marked differences in the spectrum 
of mutations between tumour types. For example, the c.2573T>G missense mutation, re-
sulting in the L858R substitution, is found in ~10–15% of all pulmonary adenocarcinomas 
(4). This mutation is the most frequent of all mutations in EGFR but has thus far never been 
identified in glioblastomas (GBMs) (3). The most common mutations in GBMs affect the 
extracellular domain of EGFR, including EGFRvIII (~30% of all GBMs) and the A289V and 
V598V missense mutations (3). These extracellular domain mutations are not found in 
pulmonary adenocarcinomas (4). One of the explanations for these tumour-type specific 
mutations is that each mutation invokes a unique signal transduction cascade. Indeed, 
EGFRvIII and EGFRwt have differential activation of the JNK, STAT and MAPK signalling 
pathways and induce the expression of a unique set of genes (9–13). Because different 
tumour types may be dependent on the unique pathways that are activated by different 
EGFR mutations, studying these functional differences between mutations may identify 
novel, tumour type specific treatment targets. Here, we have further evaluated differential 
activation of signal transduction pathways by EGFR-wt, EGFR-L858R and EGFRvIII.
METhods
EGFRvIII and EGFR-L858R cDNAs were obtained from Addgene (Cambridge, MA), EGFR 
wildtype was a gift from Ton van Agthoven and cloned into pcDNA3.1/CT-GFP- TOPO 
(Invitrogen, Bleiswijk, the Netherlands). A biotin tag and eGFP were inserted C- terminal 
to the transmembrane domain of EGFR to retain the integrity of the C-terminal (intracel-
lular) domain of EGFR. To demonstrate functionality, we transfected EGFRbio- GFP into 
ZR-75-1 cells. Normally, ZR-75-1 cells do not proliferate in the presence of tamoxifen (43). 
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However, ZR-75-1 cells expressing EGFR-bioGFP, cultured in the presence of tamoxifen, 
responded to EGF stimulation by an increase in cell proliferation, demonstrating the 
construct remained functional (not shown). Stably transfected HOG (human oligoden-
droglioma cells (44)) cell lines were created by transfection, geneticin selection and FACS 
sorting. Stable cell lines were derived from bulk culture and not form a single sorted cell 
followed by clonal propagation.
Migration and proliferation assays were performed using an Incucyte (Essen Biosci-
ence, Ann Arbor, MI). For proliferation experiments, 50,000 cells/well were plated in a 
24-well Greiner plate (Greiner Bio-One, Alphen a/d Rijn, the Netherlands). Growth curves 
were constructed using the Confluence v1.5 metric of the Incucyte software. For migra-
tion experiments, cells were grown to confluence in a 24-well Essen ImageLockplate 
after which a cell-free zone (scratch) was created using a WoundMaker. Wells were then 
cultured in serum-free media.
Constructs containing EGFRwt-BG, EGFRvIII-BG and EGFRL858R-BG were transfected into 
HEK cell lines using Polyethylenimine ‘Max’ (Polysciences, Eppelheim, Germany). The 
EGFRwt-BG, EGFRvIII-BG and EGFRL858R-BG proteins were then isolated using Dynabeads (Life 
Technologies, Carlsbad, CA, United States of America (USA)) as described previously 
(39). Purified proteins were washed and loaded on a SDS page gel. Nanoflow LC-MS/MS 
analysis was performed essentially as described by van den Berg et al. (45). Candidate 
binding proteins that were present in a GFP control pulldown or identified in >10% of 
CRAPome experiments were omitted from the analysis (14). We focused on candidate 
binding proteins that were identified with MASCOT scores >300. Western blots were 
performed as described (39). Antibodies used were DOCK4 (1:100), UGGT1 (1:100), 
DDX21 (1:500) all from Sigma–Aldrich (Zwijndrecht, the Netherlands), EGFR (1:1000, Cell 
Signaling, Boston, MA) and GFP (1:5000, Abcam, Cambridge, United Kingdom (UK)).
Cells (HOG, U87MG, HEK) were cultured on glass slides for immunocytochemistry. 
Glioma samples were obtained from the Erasmus MC glioma tissue bank. Use of patient 
material for current study was approved by the Institutional Review Board. Antibodies 
used for immunocytochemistry and/or proximity ligation assays were EGFR (1:200, 
DAKO, Heverlee, Belgium) and DOCK4 (1:100), MYCBP2 (1:200) and SMTN1 (1:100) all 
from Abcam. Proximity ligation assays were performed using a Duolink (Sigma–Aldrich) 
kit according to the manufacturer’s instructions.
HEK cells were transiently transfected with EGFRbioGFP, EGFRL858R-bioGFP and EGFRvIII-
bioGFP or BIO-eGFP constructs. Twenty hours after transfection, cells were FACS sorted 
to select for eGFP expressing cells. Cells were then snap frozen in liquid nitrogen and 
stored at -80°C. RNA extraction was performed using TriZol (Invitrogen) and checked for 
RNA quality on a Bioanalyzer (Agilent, Amstelveen, the Netherlands). Gene expression 
was performed using HU133 plus2 arrays (Affymetrix, High Wycombe, UK) run by AROS 
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Applied Biotechnology (Aarhus, Denmark). All experiments were performed in triplicate 
with each replicate experiment performed on separate days.
For reversed phase protein array (RPPA) analysis, stably transfected HOG cells were 
plated in six well plates and incubated in serum supplemented medium, or serum de-
pleted medium (24 h depletion) ± 200 ng EGF for 5 min. RPPA arrays were performed by 
the MD Anderson RPPA core facility. Luciferase activity was measured by Dual–Lucifer-
ase Reporter Assay System (Promega). Pathway analysis was performed using Ingenuity 
(Redwood City, CA) and David (46).
REsuLTs
We first generated constructs of wildtype EGFR and of two common mutations, EGFRvIII 
and L858R, and inserted a biotinylation tag and eGFP in-frame and Cterminal to the trans-
membrane domain. Constructs are referred to as EGFRwt-BG, EGFRvIII-BG and EGFRL858R-BG re-
spectively. Mass spectrometry following pulldown of biotinylated constructs identified 
over 3000 candidate binding partners for at least one of these constructs. When filtering 
for duplicate hits, and removal of proteins identified by a bio-eGFP control pulldown or 
present in >10% of crapome pulldown experiments (14), our list of candidate EGFR bind-
ing proteins included 87 unique proteins (Supplementary Table 1). Almost half (37/87) of 
these binding partners are known interactors of EGFR and include CBL, PIK3CA, PIK3R3, 
SHC1 and SOS1 (15–17).
Ingenuity pathway analysis indicated that the candidate EGFR associated proteins are 
involved in EGF signaling and Clathrin mediated endocytosis signalling. Candidate EGFR 
interacting proteins are enriched for proteins that are somatically mutated in GBMs. For 
example, 7/87 (8.0%) genes are mutated at a population frequency >1.5% (i.e. mutations 
found in at least 5/290 tumours) in the TCGA, a 3–4- fold enrichment compared to all genes 
mutated at this frequency in GBMs (485/~20.000 genes, 2.4%, P = 0.007, Fishers’ exact test).
Of the 87 candidate binding proteins, 22 showed selective association to one of the 
EGFR constructs (Table 1). Selective association was defined as a relative difference in 
mascot scores >3, and an absolute difference in mascot scores >500 between any of 
the three constructs. The strongest candidate proteins included DOCK4 (dedicator of 
cytokinesis 4) UGGT1 (UDPglucose glycoprotein glucosyltransferase 1), MYCBP2 (MYC 
binding protein 2, E3 ubiquitin protein ligase) and SMTN (Smoothelin).
Western blots on independent biotin pulldowns confirmed that DOCK4 binds 
preferentially to EGFRvIII-BG and EGFRwt-BG but not to EGFRL858R-BG (Figure 1b, Western blot 
experiments in two independent experiments). The association was further confirmed 
using a proximity ligation assay (PLA, Figure 1c). DOCK4 also associates with EGFR also 
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under native conditions as demonstrated by a co- immunoprecipitation using anti-EGFR 
antibodies in non-transfected HEK cells (Figure 1d).
Furthermore, PLA confirmed that DOCK4 and EGFR are also colocalised in EGFR amplified 
GBMs (Figure 1e). DOCK4 remains associated with EGFR-wt in cells that were serum starved 
overnight followed by EGF stimulation (Supplementary Figure 1). These data demonstrate 
that DOCK4 associates with EGFRwt-BG and EGFRvIII-BG and not (or to a lesser extent) with 
EGFRL858R-BG.
Because DOCK4 has been implicated in wnt pathway activation (18) we screened 
for differential activation of this pathway activation by the different EGFR constructs. 
However, both under basal and under wnt activated conditions, no differences in wnt 
pathway activation were identified (n = 3 independent experiments, data not shown).
Mass spectrometry also highlighted that UGGT1 and MYCBP2 preferentially associate with 
EGFRvIIIBG and that SMTN preferentially associates with EGFRL858R-BG. PLA assays confirmed the 
association for all three proteins (Figure 2), Western blot (WB) further confirmed the associa-
Table 1. Proteins showing selective binding to one or more specific Epidermal growth factor receptor 
(EGFR) mutations.
symbol EGFR wt EGFR V111 EGFR-p.L858R
AP1B1 961
CRKL 561 740 229
DNM2 462 798 211
DOCK4 2725 2136 536
EXOC7 533 213
IFI16 772 1079
IPO5 1403 411 217
LAD1 106 669 1056
LMO7 340 1362
MYCBP2 1606
MYO1E 156 503
NGLY1 353 1310 887
PIK3CA 147 902 86
PIK3CB 474 828 72
RTCB 558 341
SEL1L 604 174
SMTN 546
SPECC1L 69 909
SVIL 160 741
TNPO2 410 515
UBE3C 157 828 280
UGGT1 1573
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EGFRwt-BG, EGFRvIII-BG or EGFRL858R-BG associate with specific proteins. (A) Mass spectrometry results 
for DOCK4 and UGGT1 showing differential binding to EGFR mutations. (B) Confirmation of the mass spec-
trometry results by Western Blot on an independent pulldown. (C) A proximity ligation assay confirms that 
DOCK4 colocalises with EGFRwt-BG and EGFRvIII-BG but not with EGFRL858R-BG or Bio-GFP control (not 
shown). All images taken at 63x magnification. (D) Native EGFR also associates with DOCK4 as determined 
by immunoprecipitation of EGFR. (E) A proximity ligation assay shows that DOCK4 and EGFR also colocalise 
in tumours.
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figure 2.
EGFRwt-BG, EGFRvIII-BG or EG-
FRL858R-BG associate with specific 
proteins. A proximity ligation assay 
shows that UGGT1 colocalises with 
EGFRwt-BG and EGFRvIII-BG but not 
with EGFRL858R-BG or Bio-GFP con-
trol (see also Figure 1B). Similarly, 
MYCBP2 colocalises predominantly 
with EGFRvIII-BG whereas SMTN 
predominantly colocalises with 
EGFRL858R-BG. All images taken at 
63x magnification.
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tion of UGGT1 with EGFRvIII-BG (Figure 1 b). It should be noted that some (minor) association of 
UGGT1, MYCBP1 and SMTN to other EGFR constructs were found by PLA and/or WB.
We hypothesised that the selective association of different EGFR mutations ultimately 
would result in the induction of a unique set of genes. We have therefore performed 
gene expression profiling of cells expressing EGFRwt-BG, EGFRvIII-BG, EGFRL858R-BG or BIOeGFP 
constructs (n = 3 per construct). Statistical analysis of microarrays (SAM) identified 74, 
109 and 187 probesets that were differentially expressed in EGFRwt-BG, EGFRvIII-BG and 
EGFRL858R-BG expressing cell lines compared to BIO-eGFP control (with differential expres-
sion >2 and at a false discovery rate (fdr) <0.05, Supplementary Table 2). These probesets 
correspond to 61, 89 and 156 genes respectively. Many of these genes are found in all 
three comparisons and are involved in the transcription of DNA and are significantly en-
riched for the gene-ontology (GO) terms ‘sequence-specific DNA binding’, ‘transcription 
factor activity’, ‘transcription regulator activity’, ‘DNA binding’ and ‘protein dimerization 
activity’ (all P < 0.001). Top networks identified by Ingenuity pathway analysis include 
‘Cellular compromise, cellular function and maintenance, gene expression’, ‘develop-
mental disorder, hereditary disorder, neurological disease’ and ‘neurological disease, 
cell-mediated immune response, cellular development’.
To determine whether specific mutations have specific gene-expression signatures, we 
performed SAM analysis comparing gene expression between the different EGFR mutations. 
A total of 17, 12 and 35 probesets were identified that were differentially expressed between 
EGFRwt-BG versus EGFRvIII-BG, EGFRwt-BG versus EGFRL858R-BG and EGFRvIII-BG versus EGFRL858RBG re-
spectively (with differential expression >2 and fdr <0.2, Table 2, Figure 3). These probesets 
correspond to 15, 11 and 26 different genes respectively. Genes specifically induced by 
EGFRvIII-BG expression include SOCS3, C10ORF10 and DTX3L (~10, 4, and 2-fold induction 
respectively). EGFRL858R-BG specifically induces the expression of ARC, TFPI2, SGMS2, ARLB5 and 
CCNA1 (~8, 8, 3, 2 and 4-fold respectively). Gene expression analysis therefore indicates that 
different mutations in EGFR induce the expression of a unique set of genes.
We next analysed phosphoprotein levels by RPPA arrays on HOG cells stably ex-
pressing EGFRwt-BG, EGFRvIII-BG, EGFRL858R-BG or Bio-eGFP control. Three conditions were 
examined: normal (serum supplemented cell culture), serum free and serum free, EGF 
stimulated. All data are listed in Supplementary Table 3. Analysis of EGFR on these ar-
rays demonstrates that all stably transfected cell lines, apart from the Bio-eGFP control, 
have increased levels of EGFR and show increased EGFR phosphorylation on pY1068 and 
pY1173. Serum deprivation does not result in a loss of EGFR phosphorylation (pY1068 
and pY1173) which suggests that EGFR signalling remains active under these conditions. 
Finally, EGF stimulation results in a strong increase in EGFR_pY1068 (and to a lesser 
extent in pY1173), predominantly in EGFRwt-BG and EGFRL858R-BG expressing cells but also 
in BIOeGFP and expressing cells. EGF stimulation does not activate EGFRvIII-BG which is 
in-line with the fact that this mutation affects the EGF binding domain.
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figure 3.
Genes that are differentially expressed between 
EGFRwt-BG versus EGFRvIII-BG, EGFRwt-BG versus EG-
FRL858R-BG, and EGFRvIII-BG versus EGFRL858R-BG 
as identified by SAM analysis. Bio-eGFP control is 
included for reference. Scales are colour coded from 
13.0 (red), 7.0 (grey) to 4.5 (blue) as RMA expression 
values. (For interpretation of the references to colour 
in this figure legend, the reader is referred to the web 
version of this article.)
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Table 2. Probesets that are differentially expressed between EGFRwt-BG v. EGFRvIII-BG, EGFRwt-BG v. EG-
FRL858R-BG, and EGFRvIII-BG v. EGFRL858R-BG as identified by SAM analysis
Gene_Symbol Probeset_ID eGFP EGFRwt EGFRvIII EGFR-p.L858R wt v vIII wt v L858R vIII v L858R
SOCS3 227697_at 4.5 4.9 9.1 5.6 X X
RAP1A 1555339_at 13.4 4.9 7.0 4.7 X X
C10orf10 209183_s_at 6.6 6.8 8.9 6.8 X X
Hs.527973 206359_at 4.3 4.6 6.6 4.9 X X
RAP1A 1555340_x_at 14.3 5.5 7.3 5.1 X X
XR_132893 1565830_at 6.0 4.6 6.0 5.0 X
SOCS2 203372_s_at 6.8 6.9 7.9 7.4 X
WDR78 1554140_at 6.5 5.1 6.5 5.7 X
DTX3L 225415_at 6.6 6.5 7.4 6.6 X
BC042589 235456_at 7.8 6.4 7.4 6.9 X
KIAA1267 224489_at 6.8 6.0 6.9 6.4 X
RAB30 229072_at 6.1 4.9 6.0 5.1 X
AK022645 232257_s_at 5.2 4.1 5.2 4.5 X
HSPA6 213418_at 4.8 8.2 6.7 9.3 X X
EGR1 201693_s_at 6.0 8.9 7.7 10.9 X X
EGR1 201694_s_at 8.2 11.2 10.2 12.6 X X
EGFR 210984_x_at 5.6 10.0 9.0 10.8 X
AKIRIN2 223143_s_at 5.1 5.0 5.8 6.1 X
ARC 210090_at 5.8 6.8 6.3 9.3 X
ARL5B 242727_at 5.9 6.1 6.0 7.3 X X
CCNA1 205899_at 3.9 4.5 3.9 5.9 X X
EGR3 206115_at 5.6 7.1 6.1 9.3 X X
FOS 209189_at 5.2 7.1 7.2 9.1 X
IL12A 207160_at 5.4 5.7 5.8 6.9 X
PHLDA1 217997_at 4.6 4.6 4.6 5.9 X
SGMS2 242963_at 5.1 5.1 5.1 6.5 X
TAC1 206552_s_at 4.8 6.7 6.0 8.2 X X
TFPI2 209277_at 3.6 4.1 3.6 6.3 X X
TFPI2 209278_s_at 5.4 6.6 5.6 8.7 X X
HSPA1L 210189_at 7.5 8.2 7.4 8.7 X
HSPH1 208744_x_at 9.4 9.7 9.2 10.3 X
DNAJB1 200666_s_at 9.4 10.8 9.9 11.8 X
LOC100652898 227404_s_at 6.5 9.5 8.4 10.7 X
INSIG1 201627_s_at 11.0 11.5 10.6 11.7 X
DUSP6 208891_at 6.0 8.1 7.6 8.6 X
DNAJB1 200664_s_at 8.2 9.6 8.7 10.7 X
ANXA1 201012_at 6.1 6.8 6.6 7.8 X
KCTD12 212188_at 8.9 9.7 8.9 10.7 X
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To determine whether specific mutations induce differences in their downstream 
pathway activation, we screened all proteins that showed a >2-fold change in levels be-
tween different constructs (Figure 4). Examples of differences identified include, under 
serum conditions (i) lower levels of AKT-pT308 (and AKT_pS473) in EGFRL858R-BG express-
ing HOG cells compared to EGFRwt-BG, EGFRvIII-BG or BIO-eGFP expressing cells; (ii) lower 
levels of MAPK_pT202 phosphorylation in EGFRvIII-BG expressing cells compared to those 
expressing EGFRwt-BG and EGFRL858R-BG.
Virtually identical data were obtained in an independent RPPA experiment (Figure 4, 
and Supplementary Figure 2). Western blot experiments (independently performed) 
further confirmed the differences in AKT-pT308 and MAPK_pT202 phosphorylation 
(Figure 4). These data therefore indicate that different mutations in EGFR can induce a 
differential downstream pathway phosphorylation.
Because our results indicate that each mutation has unique molecular properties, we 
determined whether the various forms of EGFR also differentially affect cell physiology. 
HOG cells stably expressing EGFRvIII-BG and EGFRL858R-BG showed a decreased proliferation 
compared to bio-eGFP or EGFRwt-BG expressing cells (Figure 5). The differences between 
constructs were consistently observed over multiple experiments (n = 4 experiments, six 
wells/experiment and four locations/well). In a wound healing assay, the EGFRvIII-BG and 
EGFRL858R-BG expressing HOG cells also had a significantly slower migration compared to 
bio-eGFP or EGFRwt-BG expressing cells (P< 0.001, for all comparisons Figure 5). The differ-
ence between constructs was consistently observed in two independent experiments 
(n = 2 experiments, six wells/experiment and three locations/ well). These data therefore 
indicate that different mutations differentially affect cell physiology.
Table 2. Probesets that are differentially expressed between EGFRwt-BG v. EGFRvIII-BG, EGFRwt-BG v. EG-
FRL858R-BG, and EGFRvIII-BG v. EGFRL858R-BG as identified by SAM analysis (continued)
Gene_Symbol Probeset_ID eGFP EGFRwt EGFRvIII EGFR-p.L858R wt v vIII wt v L858R vIII v L858R
HSPA6 117_at 5.4 7.0 6.0 7.9 X
DUSP6 208892_s_at 5.1 7.3 6.8 7.9 X
KCTD12 212192_at 9.8 10.2 9.7 10.8 X
ZCCHC12 228715_at 9.0 10.0 9.0 10.9 X
ETV5 203349_s_at 5.5 8.6 8.0 9.3 X
EGR2 205249_at 6.1 7.6 6.8 9.4 X
C11orf96 227099_s_at 8.5 10.3 9.5 12.0 X
GPR50 208311_at 7.2 8.0 7.2 9.1 X
DOK5 214844_s_at 4.4 5.1 4.5 6.0 X
INSIG1 201625_s_at 9.2 9.8 9.0 10.2 X
Differentially expressed genes (>2 fold change in expression level, fdr <0.2) between mutations are marked 
with X in one of the last three columns.
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original (exp-1) and confirmation (exp-2) are shown. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.)
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dIscussIoN
In this study, we demonstrate different mutations in EGFR associate with different 
proteins, activate unique downstream signalling pathways (as shown by the induction 
of a unique set of genes and protein phosphorylation) and that cell lines expressing 
different EGFR mutation constructs display differences in physiology (proliferation and 
migration). Our data therefore demonstrate that different mutations have different 
functional consequences, which may provide an explanation for a tumour type specific 
mutation spectrum. Our data are in line with other studies that highlighted differences 
between wildtype EGFR, EGFRvIII and/ or EGFR p.L858R. For example, wildtype EGFR and 
EGFRvIII induce phosphorylation of different substrates, have differential activation of 
the JNK, STAT and MAPK signalling pathways, induce the expression of a unique set of 
genes and have differences in nuclear localisation (9–13,19). Our data are also in line 
with a study showing that both wt EGFR and EGFRvIII interact with DNA–Protein Kinase 
(PRKDC) whereas EGFR p.L858R does not (19): our biotin pulldown showed a ~two fold 
reduction in association with PRKDC of EGFRL858R-BG compared to both EGFRwt- BG and EG-
FRvIII-BG (Supplementary Table 1). We did not observe differential association of EGFRwt-BG, 
EGFRvIII-BG and EGFRL858R-BG with CBL proteins, see (20) . However, binding to Cbl proteins 
occurs only after stimulation with EGF, whereas our cells were not EGF stimulated.
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figure 5.
Mutations in EGFR differentially affect 
proliferation (top) and migration (bot-
tom) in HOG cells stably transfected with 
EGFRwt-BG, EGFRvIII-BG, EGFRL858R-BG 
or Bio-eGFP control. EGFRvIII-BG and 
EGFRL858R-BG have virtually identical 
migration.
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Apart from EGFR, a few proteins also show mutation specific binding partners and dif-
ferential activation of downstream signalling pathways. Examples include TP53 (R273H 
and R267P) and PIK3CA (21–24).
Because tumours often remain dependent on their acquired genetic changes for 
growth, these changes are direct targets for treatment. However, when each mutation 
activates a unique set of downstream pathways, it is possible each mutation will require 
specific inhibition. Indeed, different mutations in EGFR show differential sensitivity to-
wards inhibitors: activating mutation in the kinase domain are associated with response 
to erlotinib and gefitinib whereas the EGFR p.A289D mutation is more sensitive to inhibi-
tion by lapatinib (7,25,26) . Moreover, kinase domain mutations do not occur in GBMs 
and inhibitors that act on these mutations (erlotinib and gefitinib) do not show clinical 
benefit in GBM patients eventhough EGFR is a driver in GBMs (27,28).
Our experiments demonstrate that a number of proteins differentially associate with 
EGFR constructs. It is interesting to note that mutations in DOCK4, UGGT1, MYCBP2 and 
SMTN have been found both in GBMs (2/283, 4/283, 1/283 and 1/283 respectively) and 
pulmonary adenocarcinomas (16/220, 7/220, 17/ 220 and 4/220). The first of these pro-
teins that was further examined, DOCK4, associates with EGFRvIII-BG and, to a lesser extent, 
with EGFRwt-BG (but not with EGFRL858R-BG). DOCK4 is mutated in various tumours including 
bladder (~10%), colorectal (~10%) and lung (~7%). Two mutations in DOCK4 have thus 
far been identified in GBMs. DOCK4 is involved in cell migration through the activation of 
RAC1 (29,30). Whether the difference in cell migration between EGFRwt-BG and EGFRvIII-BG is 
due to differential association with DOCK4 remains to be determined. DOCK4 also func-
tions as a scaffold protein within the Wnt signaling pathway and is essential for activa-
tion of this pathway in vivo (18). However, we did not find a mutation specific activation 
of the WNT pathway.
A second differential binding protein, UGGT1, was found to predominantly associate 
with EGFRvIII-BG. UGGT1 plays a central role in the quality control of protein folding in the 
endoplasmic reticulum (glycosylated proteins) where it promotes substrate solubility 
(31) . It was recently demonstrated that the L858R mutation in EGFR reduces the dis-
organised conformation of the protein (32) . Because UGGT1 is involved in the quality 
control of protein folding, it is possible that the lack of association between UGGT1 and 
EGFRL858R-BG identified in our study may be a result of an altered (i.e. less disorganised) 
conformation.
Similar to UGGT1, MYCBP2 also showed preferential association with EGFRL858R-BG. 
MYCBP2 encodes an E3 ubiquitin ligase which mediates the ubiquitinylation and sub-
sequent degradation of target proteins. The protein is involved in the regulation of the 
mTOR pathway: knockdown of MYCBP2 inhibits the mTOR pathway (33). Finally, SMTN 
showed preferential association with EGFRL858R-BG. SMTN co-localised with α-actin and 
is involved in the contraction of smooth muscle cells (34). Whether the differential as-
98 Chapter 4
sociation with specific EGFR mutations affects the mTOR pathway or actin dynamics in 
tumour cells remains to be determined.
EGFR is a member of the ERBB protein family, a family of proteins that plays a role in 
several cancer types (35). The various ERBB family members can heterodimerise with 
each other, and each heterodimer can activate different signal transduction pathways 
(35,36). Although we demonstrate in this manuscript that different EGFR mutations 
activate unique molecular pathways, it remains to be determined whether the differ-
ent mutations in EGFR also result in different heterodimerisation induced pathway 
activation. Of note, the various ERBB family members do not overtly show a tumour type 
specific mutation pattern (4,37).
Our results show that expression of EGFRvIII-BG or EGFRL858R-BG in HOG cells results in a 
decreased proliferation and migration, which may be counterintuitive for an oncogene. 
However, such reduced proliferation has been observed before in mutant melanoma cells 
where expression of EGFR confers a growth disadvantage that is further strengthened 
by the addition of EGF (38). Perhaps this is caused when an oncogene (such as EGFR) 
is expressed in cells that have never been dependent on the oncogene (or the various 
mutations therein). A similar growth disadvantage (and altered migration pattern) was 
observed when expressing mutant (R132H) IDH1 into cell lines (39,40). Interestingly, 
IDH1 also has a tumour-type specific mutation pattern (41,42).
In summary, our results indicate that there are distinct differences between different 
mutations in EGFR. Whether these different mutations also have different oncogenic 
properties remains to be determined. However, these functional differences can lead to 
the identification of mutation-specific EGFR inhibitors.
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absTRacT
Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include 
mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1. However, it is generally 
assumed that more somatic mutations are required for tumorigenesis. This study aimed 
to establish whether genes mutated at low frequency can be involved in OD initiation 
and/or progression. We performed whole-genome sequencing on three anaplastic 
ODs with 1p/19q co-deletion. To estimate mutation frequency, we performed targeted 
resequencing on an additional 39 ODs. Whole- genome sequencing identified a total of 
55 coding mutations (range 8–32 mutations per tumor), including known abnormalities 
in IDH1, IDH2, CIC and FUBP1. We also identified mutations in genes, most of which were 
previously not implicated in ODs. Targeted resequencing on 39 additional ODs con-
firmed that these genes are mutated at low frequency. Most of the mutations identified 
were predicted to have a deleterious functional effect. Functional analysis on a subset of 
these genes (e.g. NTN4 and MAGEH1) showed that the mutation affects the subcellular 
localization of the protein (n = 2/12). In addition, HOG cells stably expressing mutant 
GDI1 or XPO7 showed altered cell proliferation compared to those expressing wildtype 
constructs. Similarly, HOG cells expressing mutant SASH3 or GDI1 showed altered migra-
tion. The significantly higher rate of predicted deleterious mutations, the changes in 
subcellular localization and the effects on proliferation and/or migration indicate that 
many of these genes functionally may contribute to gliomagenesis and/or progression. 
These low-frequency genes and their affected pathways may provide new treatment 
targets for this tumor type.
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INTRoducTIoN
Oligodendrogliomas (ODs) account for 20 % of all glial tumors and are thought to arise 
from oligodendroglial precursor cells (OPCs). They are classified as either grade II or 
grade III and have a more favorable clinical and prognostic outcome with respect to 
other gliomas (1).
Frequently occurring driver mutations in oligodendrogliomas include mutations in 
IDH1, CIC, FUBP1, TERT promoter and NOTCH (2–6). However, tumor formation is assumed 
to require more somatic mutations (7). Interestingly, many other somatic mutations 
within proteincoding genes have also been identified in oligodendrogliomas, albeit at a 
low frequency (8). The role of most of these infrequent mutations in tumorigenesis and/
or progression is unclear. To date, only few studies have suggested a functional impact 
of genes mutated at low frequency in gliomas (9–13). Therefore, low-frequency genes 
that play a role in the initiation and/or progression of ODs need to be identified to better 
understand OD pathogenesis and for development of targeted therapies.
Here, we have performed whole-genome sequencing on three ODs to identify all 
genetic changes in these tumors. We then performed targeted resequencing on an 
additional 39 tumors to demonstrate that many of these mutations occur at low fre-
quency. Functional analysis of a subset of these low-frequency genes (NTN4, GDI1, 
MAGEH1, SASH3, ZNF238, OR5D14, ZNF57, DCUN1D2, ARSE, XPO7, GABRE and PGLYRP4) 
suggest that they can contribute to tumor pathogenesis and therefore are unlikely to be 
passengers. These genes and their affected pathways open up entirely novel treatment 
targets for this tumor type.
MaTERIaLs aNd METhods
Patient material
OD samples were collected from the Erasmus MC tumor archive. Use of patient material 
was approved by the Institutional Review Board and patients provided written informed 
consent according to national and local regulations for the clinical study and correlative 
tissue studies. After surgical resection, all samples were snap-frozen and stored at - 80°C. 
Non-neoplastic DNA was isolated from blood and stored at - 80. Assessment of 1p19q 
LOH was performed previously (14, 15). Patient characteristics are listed in supplemen-
tary Table 1.
dNa extraction and sequencing
Tumor DNA was extracted from fresh frozen (FF) tumor samples using the AllPrep DNA/
RNA mini kit (Qiagen, Venlo, the Netherlands). Matched normal DNA was isolated from 
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1 ml blood as part of routine diagnostic procedures. Whole-genome sequencing was 
performed by Complete Genomics (Mountain View, US) using 5 l g DNA. Whole-genome 
sequencing data analysis was performed using cgatools version 1.4.0 and described 
in supplementary methods. All mutations were validated by Sanger sequencing. Tar-
geted resequencing on an additional 39 ODs was performed by Baseclear (Leiden, the 
Netherlands). Library construction and resequencing data analysis were described in 
supplementary methods.
cell lines and sorting
Constructs of wildtype and mutated genes were generated by site directed mutagenesis 
(n = 12), and C-terminally fused to GFP for visualization. Subsequently, Human oligoden-
droglial (HOG) cells (16) and HEK 293 cells were transiently transfected with wildtype 
or mutant constructs using lipofectamine according to the manufacturer’s instructions. 
Stably transfected HOG cells were created as described in supplementary methods.
functional analysis
For proliferation experiments, cells (50.000 cells/well) were plated in a 24-well Greiner 
plate (Greiner Bio-One, Alphen a/d Rijn, the Netherlands) and followed using an Incu-
cyte (Essenbioscience, Hertfordshire, United Kingdom). Growth curves were constructed 
using the Confluence v1.5 metric of the Incucyte software.
For migration experiments, cells were grown to confluence in a 24-well Essen Im-
ageLockplate after which a cell-free zone (scratch) was created using a WoundMaker. 
Wells were then washed in PBS after which serum-free media was added to the plates. 
All plates were followed for 5 days and images were automatically captured at 3-h in-
tervals from 3 to 4 separate regions within a well. Relative wound density, wound width 
and wound confluency curves were constructed using data points of every capture. 
All proliferation and migration experiments were performed at least in triplicate. Flow 
cytometric cell cycle analysis using propidium iodide was performed as described in 
supplementary methods.
REsuLTs
Whole-genome sequencing
To identify somatic alterations in oligodendrogliomas, we performed whole-genome 
sequencing on DNA of three ODs and their matched germline DNA. All tumors were 
WHO grade III and had 1p19q co-deletion. The mapped sequence of the six samples 
varied between 237 and 249 Gb, resulting in a coverage between respectively 83 and 
90-fold per genome. Confident diploid calls could be made for 94–95 % of the reference 
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genome. On average 3,5 million genetic variants were identified per sample. Of these, 
55 (range of 8–32 variants per sample), were localized to coding exons, were neither 
synonymous nor present in dbSNP130 and had a somatic score [- 20 (see supplementary 
methods) (Figure 1). Identified variants consisted of missense (84 %), nonsense (9 %) and 
frameshifts (7 %). All 55 mutations were validated by Sanger sequencing (supplemen-
tary Table 2).
We performed an in silico analysis on all 55 genes to estimate the effect of mutation on 
protein. Polyphen-2 predictions were available for 43 genes of which 22 were probably 
damaging, 9 possible damaging, and 12 were benign. In randomly picked mutations 
identified with a lower confidence score (i.e. somatic scores B- 20) the rate of damaging 
mutations was significantly lower: 10 probably damaging, 8 possible damaging and 21 
benign changes, (p = 0.033, Chi square test). The identified mutations also had a slight 
tendency towards a higher conservation compared to mutations with somatic scores 
B- 20: GERPscore 2.71 ± 2.96 v 1.75 ± 3.61 p = 0.156). The 55 mutations identified by 
whole-genome sequencing therefore were often predicted to have deleterious effects 
on the protein.
Targeted resequencing
Because we aimed to determine functional effects of genes mutated at low frequency 
in gliomas, we performed targeted resequencing of 44 (of the 55 identified by wholege-
nome sequencing) genes that were thusfar not implicated in gliomagenesis (supple-
mentary Table 2). Resequencing was performed on the entire coding region of the 44 
genes on 39 grade II/III ODs of which 28/39 had 1p/19q LOH, 5/39 had loss of 1p or 
19q and 6/39 had no 1p19q loss. We chose this dataset because it represents a typical 
cohort of histologically diagnosed oligodendrogliomas where most will have 1p19q 
co-deletion, but some have other, more aggressive genetic changes.
No mutations were found in 39 of the 44 genes in any of the additional 39 tumors. 
Of the remaining five genes, mutations were identified in only one additional sample 
(Figure 2, supplementary Table 4). In our samples, the mutations were all present at a 
high allele frequency (range 39–84 %) suggesting that the mutation is present in a large 
proportion of the resected tumor, at least within the tissue investigated. Among the 28 
tumors with 1p19q co-deletion, mutations in only three of the 44 genes were identified 
(supplementary Table 5). Although in individual tumors the allele frequency was high, 
the overall mutation frequency of all 44 genes was low. The mutations in the 44 genes 
identified by our screen therefore are ‘low-frequency genes’: genes mutated at low 
frequency in oligodendrogliomas.
Apart from these low-frequency genes, we included a set of known cancer genes 
(IDH1, IDH2, PTEN, TP53, NOTCH1, EGFR, CDKN2A, CDKN2B, NF1 and PIK3R1) for reference 
on our targeted resequencing effort. Analysis of these known cancer-relevant genes 
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revealed a total of 48 mutations (range of 1–4 mutations per tumor), which consisted of 
missense (44) and nonsense (4) variants. These include mutations in IDH1 (34 mutations 
in 39 tumors), TP53 (4/39), NOTCH1 (3/39), EGFR (2/39), IDH2 (1/39), CDKN2A (1/39), NF1 
(1/39), PIK3R1 (1/39) and PTEN (1/39) (Figure 2, supplementary Table 4). Mutations in 
EGFR, CDKN2A and PTEN were only found in patients with intact 1p19q chromosomes. 
Targeted resequencing therefore confirmed a high frequency of mutations in genes that 
drive oligodendrogliomas.
To better determine the incidence of the identified mutations, we analyzed exome 
sequencing data of 7 oligodendrogliomas from Bettegowda et al. (2), 16 oligodendro-
gliomas from Yip et al. (5) and 170 low-grade gliomas (LGG) and 290 glioblastomas 
(GBM) (8) from the TCGA dataset. In this large dataset, most (36/44) mutations identified 
by wholegenome sequencing that thus far are not implicated in oligodendrogliomas, 
were also identified in one of these datasets; eight were uniquely identified by us. The 
frequency was however low: often only one sample was identified in the external data-
sets with a mutation in that gene (supplementary Figure1).
Mutations in low-frequency genes can affect the proteins’ subcellular localization 
In order to determine whether these low-frequency genes may be involved in glioma 
pathogenesis, we performed a more detailed molecular analysis on 12/44 of those 
genes (Figs. 3, 4, 5). These 12 genes were randomly picked from the 44 low-frequency 
genes. Transient transfection revealed that in 2/12 constructs, the mutation affects the 
proteins’ subcellular localization. In the gene NTN4, the mutation resulted in a strong 
nuclear localization, which was absent in the wildtype (Figure 3). For MAGEH1, the 
mutation resulted in a reduced or even absent nuclear localization. No differences in 
the subcellular localization between wildtype and mutant constructs were found in 
cells expressing GDI1, ZNF238, SASH3, XPO7, ZNF57, GABRE, OR5D14, PGLYRP4, ARSE and 
DCUN1D2 (not shown).
Low-frequency genes can affect proliferation and/or migration
To further examine the functional properties of low-frequency genes, we generated 
cell lines stably expressing the mutant or wildtype variant of four genes and performed 
functional analysis on proliferation and migration (Figs. 4, 5).
The first gene examined was GDI1, in which the mutation was located in the geranyl–
geranyl transferase domain (c.577C>T, p.R193C). HOG cells stably expressing wildtype 
GDI1 have increased proliferation compared to those expressing GDI1R193C or eGFP (p 
=0.003, p = 0.04, respectively, n = 2). This is also confirmed by flow cytometry, showing 
that in cells expressing wildtype GDI1, 7.5 % more cells are found in the S-G2-M phase 
and 8.5 % less in the G1 compared to those expressing GDI1R193C (supplementary Figure 
2). No differences in proliferation were observed between GDI1R193C and eGFP cells (p = 
0.7). Similarly, HOG cells stably expressing GDI1 wildtype showed increased migration 
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figure 3.
Mutations in low-frequency genes can affect the subcellular localization of proteins. HOG and HEK 293 cells 
were transiently transfected with either the wildtype or mutant construct and stained or GFP (green), DAPI 
(blue) and Alexa fluor phalloidin (red). A total of twelve wildtype and mutant construct pairs were made. In 
both cell lines, the mutated NTN4 construct showed a stronger nuclear staining pattern compared to the wild-
type construct. For MAGEH1, the mutation resulted in a reduced or even absent nuclear staining. No differ-
ences in the subcellular localization between wildtype and mutant constructs were found in HOG and HEK 293 
cells expressing GDI1, ZNF238, SASH3, XPO7, ZNF57, GABRE, OR5D14, PGLYRP4, ARSE and DCUN1D2 (not shown). 
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compared to GDI1R193C or eGFP (p = 0.003, p = 0.0005 respectively, n = 2). No differences 
in migration were observed between GDI1R193C and eGFP cells (p = 0.3). The differences in 
both proliferation and migration between wildtype and mutant constructs indicate that 
the mutation in GDI1 affects the functional property of the protein.
Our second gene examined was XPO7, in which a mutation was identified in the ARM-
type fold domain (c.709G>A, p.D237N). An increase in proliferation was observed during 
the first 24 h in cells stably expressing XPO7D237N compared to wildtype and eGFP cells 
(p = 0.02, p=0.001 (n = 2), respectively). After 24 h, the proliferation rate was similar 
in cells stably expressing wildtype, XPO7D237N and eGFP. Because of the differences in 
proliferation at the start of the experiment, XPO7D237N cells reach confluency more rapid 
than wildtype or eGFP cells. The initial difference was consistently observed in multiple 
experiments with 3–6 wells per experiment and 4 positions per well. Because cells were 
plated at 2 different densities (50.000 and 100.000 cells per well) the observed differ-
ence in initial proliferation rates appeared independent of plating density. A possible 
explanation for this difference is that XPO7D237N cells recover more rapidly after plating. 
figure 4.
Mutations in low-frequency genes can affect cell growth. a HOG cells stably expressing wildtype GDI1 show 
increased proliferation compared to GDI1R193C expressing cells (p = 0.003, n = 2 independent experiments). 
b Cells stably expressing XPO7D237N show a higher rate of proliferation during the first 24 h, compared to 
wildtype expressing cells (p = 0.02, (n = 2)). After 24 h, similar proliferation rates were observed in wildtype 
and XPO7D237N. c HOG cells stably expressing SASH3 wildtype or SASH3R288* and d wildtype or ZNF238V121I 
show similar proliferation rates (n = 3)
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Migration of cells expressing XPO7D237N or wildtype was higher than those expressing 
eGFP (p = 0.05, p = 0.03, respectively (n = 2)). No differences in migration were observed 
between cells expressing XPO7D237N and wildtype (p = 0.5). The effect of the identified 
point mutation in XPO7 on proliferation highlights its importance for protein function 
in these cells.
The third gene examined was SASH3, in which the mutation was located in the SAM 
domain (c.862C> T), partially disrupting this domain in the C-terminal region (p.R288*). 
HOG cells stably expressing SASH3 wildtype, SASH3R288* or eGFP have a similar prolifera-
tion rate (n = 3). However, cells expressing wildtype SASH3, show increased migration 
compared to SASH3R288* or eGFP. The difference in migration between wildtype and 
SASH3R288* indicates that the mutation affects the function of the wildtype protein (p = 
0.001, n = 2).
Our last gene examined was ZNF238, in which the mutation was located in a BTB/
POZ fold domain (c.361G>A,p.V121I). In HOG cells stably expressing ZNF238 wildtype or 
ZNF238V121I constructs, we observed a slight decrease in proliferation compared to eGFP 
figure 5.
Mutations in low-frequency genes can affect cell migration. a HOG cells stably expressing GDI1 wildtype 
have a higher migration rate compared to GDI1R193C expressing cells (p = 0.003, n = 2 independent experi-
ments). b No differences in migration were observed between cells expressing wildtype and XPO7D237N or 
between cells expressing ZNF238 wildtype and mutant (d) (p = 0.5). c Cells expressing wildtype SASH3, 
show increased migration compared to SASH3R288*(p = 0.039)
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expressing cells (p<0.001, n = 4).Amore pronounced effect was observed in migration: 
HOG cells stably expressing ZNF238 wildtype and ZNF238V121I show a strong decrease 
compared to eGFP. These results were consistently observed in multiple experiments 
(p< 0.001, n = 4). Although no differences were observed between wildtype and mutant 
constructs, the results do indicate that wildtype or ZNF238V121I constructs affect cellular 
proliferation and migration.
dIscussIoN
In this study, we have performed whole-genome and targeted resequencing on 3 and 
39 oligodendrogliomas to identify somatic mutations. Apart from the known frequently 
mutated genes such as IDH1, CIC and FUBP1, our study also identified genes that were 
infrequently mutated (i.e. in one or two samples only). Most low-frequency genes are 
predicted to affect the protein’s function by in silico analysis. A significantly higher 
proportion of genes had a potential deleterious effect compared to mutations in genes 
identified with a lower confidence score (i.e. somatic scores B- 20). Functional analysis 
of these low-frequency genes indicated that the identified mutation can affect protein 
subcellular localization and/or cell physiology. Our results therefore suggest that (at 
least some of ) these genes may be relevant for gliomagenesis and/or contribute to 
progression.
The frequency of mutations identified at a higher frequency in our study (IDH1, CIC 
and FUBP1) are similar to those reported by others for this tumor type. Mutations in the 
ATRX gene were not identified; this gene is frequently mutated in other glioma subtypes 
including WHO grade IIIII astrocytomas (71 %), oligoastrocytomas (68 %) and second-
ary glioblastomas (57 %) (2, 5). Also similar to reported by others, mutations in EGFR, 
CDKN2A and PTEN were mutually exclusive with 1p19q co-deletion (2–5, 8).
To our knowledge, our study is the first to functionally study low-frequency genes on 
a larger scale. Several other studies have demonstrated a functional impact of genes 
mutated at a low frequency (9–13, 17). Our data therefore are in line with the hypothesis 
that genes mutated at low frequency in gliomas can functionally contribute to glioma-
genesis.
Of the genes examined, the mutations identified in NTN4 and MAGEH1 were predicted 
as ‘‘probably damaging’’ by Polyphen-2 analysis and affected the protein subcellular 
localization. Both mutations in NTN4 and MAGEH1 are not located in any of the known 
signal peptides for protein localization. These mutations may affect protein folding and 
sorting, however this would be accompanied by an accumulation of proteins in the ER, 
and we did not observe such accumulation in our transfected cells.
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Of the genes examined in more detail, the mutation identified in GDI1 was predicted 
as ‘‘probably damaging’’ by Polyphen-2 analysis and did not affect the protein subcel-
lular localization. Our data show that HOG cells stably expressing wildtype GDI1 have 
increased proliferation and migration compared to those expressing GDI1R193C or eGFP. 
The proliferation experiments were validated by flow cytometry, showing that wildtype 
GDI1 expressing cells are more present in the S-G2-M phase and less in the G1 compared 
to mutant GDI1 expressing cells. GDI1 encodes for GDP dissociation inhibitor 1, which is 
involved in recycling of Rab proteins and contains a GTPase activation GDI1-β2/GDI1-β 
and geranyl–geranyl transferase domain (supplementary Figure 3) (18–20). The GTPase 
activating domain of GDI1 interacts with the GDP-bound Rab proteins, while the gera-
nyl–geranyl domain interacts with the prenylated binding motif of Rab protein (21).
The altered migration may be caused by a differential activation of Rab proteins by 
GDI. Rab proteins belong to the Ras superfamily and are involved in vesicle trafficking 
between cellular compartments along actin or microtubules (22). Binding of GDI to 
prenylated GDP-bound Rab protein in the cytosol mediates the delivery of Rab proteins 
to membranes during vesicle formation and their return into the cytosol after vesicle 
fusion (23, 24). Importantly, Rab proteins seem to direct migration of cancer cells by 
regulating integrin recycling (25). This mutation is functionally important as mutated 
GDI1 does not stimulate cell proliferation and migration whereas wildtype GDI1 does.
The second gene examined was XPO7, in which the mutation was also predicted to 
be probably damaging by Polyphen-2 analysis. The mutation did not affect the protein 
subcellular localization. Our data indicate that both wildtype and XPO7D237N increase the 
proliferation rate of HOG cells. XPO7 encodes for exportin 7, which is a nuclear transport 
receptor that exports cargos from the nucleus into the cytoplasm (26). This protein 
contains a N-terminal Importin-beta domain that binds to RAN and an ARM-type fold 
domain (26). Its C-terminal region is thought to be involved in the recognition of sub-
strates with broad specificity (27). The fact that both wildtype and XPO7D237N stimulate 
cell proliferation and migration, highlights the importance of this gene.
The third gene examined was SASH3, in which the mutation was predicted as probably 
damaging by Polyphen-2 analysis and did not affect the protein subcellular localization. 
The current study found that cells expressing wildtype SASH3, but not SASH3R288*, show 
increased migration, indicating that the mutation affects the function of the wildtype 
protein. SASH3 encodes a signaling adapter protein, containing a SLY motif in the N-
terminal region, a SH3 motif and a SAM motif in the C-terminal region (28). SAM families 
of receptors are known to play a role in many developmental processes including cell 
migration, neuronal formation and angiogenesis (28). They seem to mediate signal 
transduction by connecting downstream effector proteins to cell surface receptors (29, 
30). The altered migration pattern in SASH3R288* expressing cells may therefore be caused 
by disturbed signal transduction pathways that lead to cell migration. This mutation is 
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functionally important as SASH3R288* does not stimulate cell migration where wildtype 
SASH3 does.
The last gene examined was ZNF238, in which the mutation was predicted as ‘‘probably 
damaging’’ by Polyphen-2 analysis and did not affect the protein subcellular localization. 
Our data indicate that cells stably expressing wildtype or ZNF238V121I decrease prolifera-
tion and migration compared to control. The present finding is consistent with other 
studies in which ZNF238 was found to decrease proliferation (31, 32) and that ZNF238 
is essential for neuronal migration in experimental mouse models (32 –34). ZNF238 en-
codes a transcriptional repressor that contains a BTB/POZ fold domain in the N-terminal 
region and four zinc fingers in the C-terminal region (35, 36). This protein family plays a 
role in many processes, including DNA damage response, cell cycle and developmental 
processes (31–34, 37). Our observation that wildtype and mutant constructs affect cel-
lular proliferation and migration, highlights the important role of this gene.
Although our data argue that many genes are functionally relevant for gliomas, there 
are some limitations to our study. For all functional experiments, we have only utilized 
the HOG cell line, as these cells have been well characterized and resemble immature 
oligodendrocytes (16). Whether these effects are retained in other cell lines remains to 
be determined. For example, to determine whether these genes indeed contribute to 
gliomagenesis, similar experiments need to be performed in stem cells, patient derived 
xenografts and various in vivo experiments. However because mutations occur at such 
low frequency, patient-derived primary cultured tumor cell lines containing these muta-
tions are hard to obtain. Moreover, oligodendrogliomas with 1p19qLOH and/or IDH1 
mutated tumors virtually cannot be propagated in vitro. Nevertheless, our data shows 
that even in a single cell line, a substantial proportion of low-frequency genes function-
ally affects cell physiology.
Another limitation of this study is that we have only performed functional analysis of 
a few genes. However, in a substantial proportion of the examined genes, the mutation 
affected the function of the wildtype protein. Our data therefore suggest that a substan-
tial proportion of low-frequency genes are functionally relevant for glioma initiation 
and/or progression.
In contrast to may be expected for oncogenic mutations, we found that the prolif-
eration and/or migration rate was reduced in cells expressing GDI1R1193C, ZNF238V121I and 
SASH3R288*. It is not uncommon for ectopic expression of oncogenes in various cell lines 
to result in reduced proliferation and altered migration. In fact, Sun et al. have shown 
that expression of EGFR in mutant melanoma cells confers a growth disadvantage that 
is further strengthened by the addition of EGFR ligand (38). A similar growth disadvan-
tage (and altered migration pattern) was observed when expressing IDH1R132H (10, 39). 
Perhaps, this is a relatively common physiological response of cells that have never been 
dependent on a specific oncogene. It is however also possible that the mutation does 
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not contribute to tumor formation/progression but simply has deleterious effects on the 
functioning of the wildtype protein.
In conclusion, we have demonstrated that low-frequency genes can affect the proteins’ 
subcellular localization and/ or physiology in HOG cells. These findings indicate that 
low-frequency genes functionally can contribute to gliomagenesis and/or progression 
and suggest these genes as new therapeutic targets for treatment for this tumor type.
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In this thesis, we have described several methods to identify prognostic and predictive 
markers in gliomas using high-throughput profiling technologies and have shown their 
clinical relevance in two randomized clinical trials (chapters 1-3). We have also evaluated 
the functional consequences of different mutations in EGFR and infrequent gene muta-
tions in ODs. We found that different mutations in EGFR can have different functional 
effects (chapter 4). Functional analyses of infrequently mutated genes in oligodendro-
gliomas have shown that the identified mutations may affect their functional properties 
(chapter 5).
Molecular markers
The diagnosis of gliomas has been primarily dependent on the histological examination 
of the tumor. However, due to histological heterogeneity of gliomas and interobserver 
variability, classification is often difficult and a more integrated diagnosis is required. 
With recent findings in molecular biology, use of molecular markers has increased in 
gliomas to assist diagnosis, prognosis and predict response to therapy.
1p19qLOH, and IDH1 mutations are molecular markers that occur early in glioma devel-
opment and enable molecular separation of gliomas into oligodendroglial (1p19q codel, 
IDH1/2, CIC, FUBP1, TERT mutations) and astrocytic lineage (IDH1, ATRX, TP53 mutations) 
in combination with other molecular markers. These markers are very powerful to aid 
classification of gliomas. Besides these markers, EGFR status and MGMT promoter meth-
ylation are also often being assessed, the latter also having predictive value in response 
to TMZ in GBMs. In this thesis, we have shown that expression-based intrinsic glioma 
subtyping has additional value by segregating tumors based on their transcriptome 
and integrating the single molecular markers in one assay. Therefore, intrinsic glioma 
subtyping represents a comprehensive and accurate method to help diagnosis, predict 
prognosis and treatment response.
High throughput profiling
For gene expression-based molecular subtyping, we made use of both micro-array 
based platform (DASL) and RNA-sequencing (RNA-seq). Both platforms showed a high 
correlation in gene expression profiles. However, RNA-seq does not rely on transcript-
specific probes, it can therefore also detect novel transcripts, gene fusions, indels and 
single nucleotide variations and is deprived of probe-dependent technical issues. This 
technology also offers a broader dynamic range than microarrays, which makes detec-
tion of more differentially expressed genes with higher fold change possible. Despite 
RNA-seq has more advantages over micro-array based platforms, until recently, the 
latter is still more commonly used, likely because RNA-seq is new to most users, more 
expensive and data analysis requires knowledge and expertise. We believe that once 
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these limitations are solved, RNA-seq will become the predominant application for gene 
expression analysis.
To bring a biomarker to the clinic, it is mandatory to show a meaningful clinical benefit, 
supported by strong validation data. Both expression profiling and methylation profiling 
have shown predictive value in EORTC 26951. As a technique however, methylation pro-
filing provides a more robust and reliable outcome as this method measures a positive 
versus negative signal (unmethylated v. methylated) compared to fold changes in gene 
expression levels. In addition methylation uses DNA, which is intrinsically more stable 
than RNA. Hence, methylation offers several technological advantages over expression 
profiling and is more applicable in the clinical setting. We therefore believe that full-
scale implementation of expression profiling in the clinical setting is not yet feasible in 
the near future, considering the costs and complexity. However expression based single 
markers, such as the genes FMO4 and OSBPL3 identified from RNA-seq data in the BELOB 
study, may be more readily implemented. It should be noted however that these specific 
markers need independent validation.
Even if more difficult to use, we have shown that expression profiling provides useful 
diagnostic and prognostic information: expression based intrinsic glioma subtypes are 
composed of different histological subtypes and have different prognosis. The predic-
tive value of response to PCV in anaplastic oligodendrogliomas of intrinsic subtypes 
however needs to be strengthened by validation in prospective clinical trials. 
High throughput DNA sequencing of clinically relevant genes is easier to perform and 
could be integrated in an assay to quickly screen tumors for a pattern. Other parameters 
affecting the choice of assay are the costs and simplicity of generated data analysis. 
To use a marker in the clinic, it should be easy to perform, cost-effective and quickly 
analyzed and reported to the clinic.
EGFR
In chapter 4, we have analyzed the functional consequences of different activating mu-
tations in EGFR. We used the most common mutation in GBM, EGFR vIII, which includes 
an in frame deletion of exons 2-7 and the common p.L858R mutation in pulmonary 
adenocarcinomas. Both mutations are constitutively activating and are not found in the 
other tumor type. We found differences in binding partners and activated downstream 
pathways between EGFR wt, vIII and EGFR p.L858R, which is in line with previous studies 
(1-6). As these mutations activate different downstream pathways, these patients may 
require mutation-specific treatment regimens.
An additional complicating factor is that even within one tumor, different mutations in 
EGFR can exist. It is possible that each activates unique pathways and they may require 
unique treatments. As EGFR inhibition in GBMs has had limited clinical benefit, novel 
EGFR inhibitors should be considered for this tumor type. However, in order to develop 
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mutation-specific EGFR inhibitors or antibodies (e.g. EGFR vIII antibody), pathways medi-
ating downstream effects of these mutations need to be well addressed and specifically 
targeted.
Low-frequency genes
The process of tumor formation requires many somatic mutations. High throughput 
efforts studying 1p19q co-deleted ODs identified frequent aberrations in the genes 
CIC, IDH1 and FUBP1. Surprisingly, little attention has been paid to the mutations whose 
frequencies in the population are low. The identification of rare mutations may provide 
exciting new treatment targets. To our knowledge, we are the first to study function-
ally low-frequency genes on a larger scale. In this thesis, we identified mutations in the 
genes NTN4, MAGEH1, GDI1, and SASH3 that affect their functional properties and may 
contribute to glioma progression. Treatment aimed at targeting a single gene may be in-
effective, as different driver mutations exist within one tumor. These affected genes are 
likely part of a molecular pathway and therefore treatment aimed at targeting pathways 
by inhibition or reactivation should be considered. Simultaneously targeting multiple 
affected pathways could give the best results.
Unfortunately, in vitro functional testing of genetic changes and affected pathways 
is time consuming, and therefore, limits the number of experiments that can be done. 
High-throughput platforms for functional testing therefore should be developed to en-
able more rapidly to distinguish driver mutations from passenger mutations, determine 
which pathways are activated and which drug (combinations) are most effective.
High throughput technologies have enabled us to perform screening of a large 
amount of patients for prognostic and predictive markers. The future challenge will be 
to translate these findings into daily clinical practice. The identified predictive markers in 
this thesis need to be functionally analyzed in vitro and in vivo and validated in large pro-
spective randomized trials. In addition, the development of novel treatments targeting 
these changes is required. Identification of novel targets and development of targeted 
treatments takes many years before implementation in the clinic, however this is the 
only way to improve patient outcome. In the future, we expect that high- throughput 
technologies will make a large contribution to a more patient specific approach with 
treatment aimed at patient specific molecular alterations.
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Gliomas are the most frequent primary brain tumors in adults. Despite multimodality 
treatment strategies, the survival of patients with a diffuse glioma remains poor. There 
has been an increasing use of molecular markers to assist diagnosis and predict prog-
nosis and response to therapy. Although several prognostic and predictive response 
markers have been identified, considerable research still needs to be done to improve 
on these. For example, there are patients with MGMT-methylated promoters who re-
spond poorly. Therefore, the identification of novel predictive response markers and 
therapeutic targets are desperately needed for this dismal disease.
In chapters 1-3, we describe prognostic and identify novel predictive markers in 
randomized clinical trials. In chapter 1, we determined the gene expression profiles of 
samples from a large European phase III clinical trial (EORTC 26951) to evaluate the treat-
ment responses within defined intrinsic glioma subtypes (IGSs). IGSs are molecularly 
similar tumors that have been previously identified by unsupervised gene expression 
analysis. In this study, we showed that gene expression profiling can be performed on 
formalin fixed-paraffin-embedded clinical trial samples. We found that all six IGSs were 
present in EORTC 26951, confirming that within a well-defined histological subtype, dif-
ferent molecular subtypes exist. In addition, we confirmed that IGS subtypes are prog-
nostic for OS: Tumors assigned to IGS-9 (characterized by tumors with a high percentage 
of 1p/19q LOH and IDH1 mutations) had the most favorable prognosis, while those 
assigned to IGS-23 (without 1p/19q LOH and IDH1 mutations) had the worst prognosis. 
Moreover, tumors assigned to IGS-9 showed benefit from adjuvant PCV chemotherapy 
and when combined with other prognostic factors (such as 1p/19q LOH and IDH1 muta-
tions), IGSs improved outcome prediction. Intrinsic subtypes can therefore be used to 
assess the molecular heterogeneity within clinical trials and may be used as a prognostic 
and predictive marker. However, for use in a clinical setting, these data require validation 
in an external dataset. 
In chapter 2, we describe another method to profile gliomas that is based on DNA- 
methylation. Methylation is a process by which methyl groups are added to cytosine 
residues, ultimately leading to inactivation of the gene. The CpG island hypermethyl-
ated phenotype (CIMP) is defined as elevated levels of DNA methylation with CIMP+ 
tumors showing better clinical response than CIMP- tumors. Besides CIMP, methylation 
of MGMT has been established as a predictive marker in gliomas. The methylation status 
of the MGMT promoter can be assessed using MGMT-STP27 prediction model. Here, we 
performed genome-wide methylation profiling on material from EORTC 26951 and as-
sessed CIMP and MGMT-STP27 status. First, we have shown that methylation profiling is 
feasible on archival samples. Then, in a univariate analysis, we have shown that survival 
in patients with CIMP+ or MGMT-STP27 methylated tumors was improved compared to 
CIMP- and/or MGMT-STP27 unmethylated tumors. Importantly, the MGMTSTP27 status 
was predictive for response to adjuvant PCV chemotherapy in these tumors. MGMT-
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STP27 may therefore be used to identify AODs and AOAs with improved prognosis and 
identify patients that are likely to benefit from adjuvant PCV chemotherapy.
In chapter 3, we describe gene expression profiling on samples of a randomized phase 
II trial (BELOB). This trial provided evidence of benefit of the addition of bevacizumab 
(Beva) to CCNU chemotherapy in recurrent GBM patients. In this study, we determined 
the gene expression profiles of BELOB samples to identify patients who benefit most 
from combined Beva+CCNU treatment. We found that tumors assigned to IGS-18 (classi-
cal GBMs) showed a trend towards benefit from Beva+CCNU treatment. No such benefit 
was found in other glioma subtypes. Expression of FMO4 and OSBPL3 were particularly 
associated with treatment response.
In chapter 4 and 5, we perform functional analysis on different mutations on the EGFR 
gene and infrequently mutated genes in oligodendrogliomas and describe the different 
functional effects of each mutation.
In chapter 4, we show that different mutations within a single gene (EGFR) can have 
different molecular consequences. We compared the most common mutation in GBM, 
EGFR vIII, with the most common mutation in pulmonary adenocarcinomas (p.L858R) 
and with EGFR wildtype. Using mass spectrometry, we showed that there are different 
binding partners for EGFR vIII, EGFR p.L858 and EGFR wildtype. Furthermore, we found 
that each mutation activates different signal transduction pathways and ultimately, re-
sults in differences in physiology (proliferation and migration). As these mutations have 
different functions, each mutation may need its own unique treatment.
In chapter 5, we identify infrequently mutated genes in oligodendrogliomas by whole 
genome and targeted resequencing and describe the functional consequences of a 
subset of those genes in silico and in vitro. Functional analysis showed that the function 
of many of ‘low frequency’ genes, differs from its wildtype counterpart. This differential 
effect suggests that these genes can contribute to the disease and therefore may offer 
new therapeutic targets for oligodendrogliomas.
In summary, we describe several new predictive markers (chapters 1-3) and describe 
the functional effects of different mutations in EGFR (chapter 4) and infrequently mu-
tated genes in oligodendrogliomas (chapter 5).
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Gliomen zijn de meest voorkomende primaire hersentumoren bij volwassenen. On-
danks multimodale behandeling, is de overleving van patiënten met een glioom nog 
steeds slecht. Tegenwoordig is er een toenemend gebruik van moleculaire markers voor 
de diagnose, prognose en om de respons op therapie te voorspellen. Hoewel verschil-
lende prognostische en predictieve respons markers zijn geïdentificeerd, moet nog 
veel onderzoek gedaan worden om deze te verbeteren. Zo zijn er patiënten met een 
gemethyleerd MGMT die het slecht doen. Daarom moeten nieuwe predictieve markers 
en therapeutische targets geïdentificeerd worden voor deze sombere ziekte.
In de hoofdstukken 1-3, beschrijven we prognostische en identificeren we nieuwe 
predictieve markers in gerandomiseerde klinische studies. In hoofdstuk 1, beschrijven 
we de genexpressie analyse van monsters uit een grote Europese fase III klinische 
studie (EORTC 26951). In deze studie zijn alle zes IGSs (IGSs zijn moleculair vergelijk-
bare tumoren die eerder zijn geïdentificeerd door een ongesuperviseerde genexpressie 
analyse) in EORTC 26951 aangetoond waarmee bevestigd wordt dat er verschillende 
moleculaire subtypen voorkomen binnen één histologische subtype. Daarnaast hebben 
we bevestigd dat deze subtypes prognostisch zijn voor overleving. Patienten met een 
IGS-9 tumor hadden de meest gunstige prognose, terwijl IGS-23 tumoren de slechtste 
prognose hadden. Bovendien hadden patienten met een IGS-9 tumor baat bij adjuvante 
PCV chemotherapie. Intrinsieke subtypen kunnen daarom worden gebruikt om de mo-
leculaire heterogeniteit in klinische studies te bepalen en dienen als prognostische en 
predictieve markers.
In hoofdstuk 2 beschrijven we een andere methode om gliomen te profileren, namelijk 
op basis van DNA methylering. Methylering is een proces waarbij methylgroepen wor-
den toegevoegd aan cytosine residuen, wat uiteindelijk leidt tot inactivatie van het gen. 
De CpG island hypermethylated fenotype (CIMP) wordt gedefinieerd als een verhoogd 
niveau van DNA methylatie waarbij CIMP+ tumors een klinisch betere respons vertonen 
dan CIMP- tumoren. Naast CIMP, heeft methylatie van MGMT gen ook een predictieve 
waarde in gliomen. De methylatie van het MGMT promotor kan worden beoordeeld met 
behulp van het MGMT-STP27 model. We hebben genome-wide methylatie gedaan op 
materiaal van EORTC 26951 en hebben de CIMP en MGMT-STP27 status bepaald. Daarna 
hebben we in een univariate analyse aangetoond dat patiënten met CIMP of MGMT-
STP27 gemethyleerde tumoren een verbeterde overleving hebben ten opzichte van 
CIMP- en of MGMT-STP27 ongemethyleerde tumoren. In een multivariate analyse was de 
MGMTSTP-27 status tevens voorspellend voor response op adjuvante PCV chemothera-
pie. MGMT-STP27 kan daarom gebruikt worden om anaplastische oligodendrogliomen 
en oligoastrocytomen met een verbeterde prognose te identificeren en het effect van 
adjuvante PCV chemotherapie te voorspellen.
In hoofdstuk 3 beschrijven we genexpressie analyse op monsters van een geran-
domiseerde fase II studie (BELOB). De BELOB studie suggereerde dat toevoeging van 
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bevacizumab (Beva) aan CCNU chemotherapie de overleving verbetert bij recidiverende 
GBM-patiënten. In onze studie laten we zien dat IGS-18 tumoren een trend hadden om 
voordeel te hebben van een gecombineerde Beva + CCNU behandeling. Een dergelijk 
voordeel werd niet gevonden in andere glioom subtypes. Expressie van FMO4 en OSBPL3 
waren vooral geassocieerd met respons op behandeling. Deze voorspellende markers 
kunnen de selectie van recidiverende GBM- patiënten die baat hebben bij Beva + CCNU 
behandeling mogelijk maken.
Hoofdstuk 4 en 5 beschrijven de functionele analyse van verschillende mutaties in 
het EGFR gen en in infrequent gemuteerde genen in oligodendrogliomen. In hoofdstuk 
4 tonen we aan dat verschillende mutaties in één gen (EGFR) verschillende moleculaire 
gevolgen kunnen hebben. We vergeleken de meest voorkomende mutatie in GBM, EGFR 
vIII, met de meest voorkomende mutatie in pulmonaire adenocarcinomen (p.L858R) met 
elkaar en met wildtype EGFR. Met behulp van massaspectrometrie, tonen we aan dat er 
verschillende bindingspartners zijn voor EGFR vIII, EGFR p.L858 en normaal EGFR. Boven-
dien tonen we aan dat elke mutatie verschillende signaal transductieroutes activeert. 
Daarnaast tonen cellijnen die stabiel EGFR vIII en EGFR L858R tot expressie brengen 
verminderde proliferatie en migratie in vergelijking met cellen die normaal EGFR tot 
expressie brengen. Aangezien deze mutaties verschillende bindingspartners hebben, 
verschillende signaaltransductieroutes aanzetten en verschillen tonen in fysiologie, is 
het mogelijk dat elke mutatie een eigen unieke behandeling krijgt.
In hoofdstuk 5 identificeren we infrequent gemuteerde genen in oligodendrogliomen 
en beschrijven we de functionele gevolgen van een subset van die genen. Functionele 
analyse toonde aan dat mutaties in een aantal genen de lokalisatie van het eiwit veran-
dert en/of fysiologie van cellen beïnvloedt. Het is daarom mogelijk dat deze genen een 
rol spelen in dit tumortype en zo als nieuwe therapeutische targets dienen.
Samengevat beschrijven we in dit proefschrift een aantal nieuwe voorspellende 
markers voor respons op therapie (hoofdstukken 1-3) en beschrijven we de functionele 
effecten van verschillende mutaties in EGFR (hoofdstuk 4) en infrequent gemuteerde 
genen in oligodendrogliomen (hoofdstuk 5).
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A Astrocytoma
AA Anaplastic astrocytoma
AOA Anaplastic oligoastrocytoma
AOD Anaplastic oligodendroglioma
CBTRUS Central Brain Tumor Registry of the United States
CCNU Lomustine
CIMP CpG island methylator phenotype
DASL cDNA-mediated Annealing, Selection, Extension, and Ligation
DNA Deoxyribonucleic acid
EGFR Epidermal growth factor receptor
EORTC European Organisation for Research and Treatment of Cancer
FDR False discovery rate
FF Fresh frozen
FFPE Formalin-fixed paraffin-embedded
FISH Fluorescence in sity hybridization
GBM Glioblastoma
IDH1 Isocitrate dehydrogenase 1 gene
IDH2 Isocitrate dehydrogenase 2 gene
IGSs Intrinsic glioma subtypes
KPS Karnofsky performance score
LOH Loss of heterozygosity
MGMT 0-6methylguanine-DNA methyltransferase
OA Oligoastrocytoma 
OD Oligodendroglioma
OS Overall survival
PA Pilocytic astrocytoma
PCR Polymerase chain reaction
PCV Procarbazine, Lomustine, and Vincristine chemotherapy
PFS Progression-free survival
RNA Ribonucleic acid
RT Radiotherapy
SNP Single-nucleotide polymorphism
TMZ Temozolomide
WHO World Health Organization
WGS Whole-genome sequencing
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